documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepsera jyseleca letairis odefsey ranexa sovaldi stribild tecartustm trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig lexiscan registered trademark astellas us llc macugen registered trademark bausch health ireland limited symtuza registered trademark janssen sciences ireland unlimited company tamiflu registered trademark hoffmannla roche inc hepcludex registered trademark myr gmbh report also refers trademarks service marks trade names companiesthis annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might forecast variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forwardlooking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs collaboration licensing arrangements ongoing litigation investigation matters statements regarding anticipated future impact business ongoing coronavirus disease covid related public health measures statements regarding development manufacturing distribution veklury treatment covid statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forward looking statements various reasons including identified part item annual report heading risk factors given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise part item business gilead sciences inc gilead us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis cancer operate countries worldwide headquarters foster city california business products innovative medicines represent advancements offering firstinclass treatments greater efficacy enhanced modes delivery convenient treatment regimens improved resistance profiles reduced side effects focus innovation allowed us deliver marketed products across multiple therapeutic areas primary revenuegenerating products approved indications united states follows hivaids biktarvy oral formulation dosed day treatment hiv infection certain patients biktarvy single tablet regimen fixeddose combination antiretroviral medications bictegravir emtricitabine tenofovir alafenamide taf genvoya oral formulation dosed day treatment hiv infection certain patients genvoya single tablet regimen fixeddose combination antiretroviral medicines elvitegravir cobicistat emtricitabine taf descovy oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients descovy fixeddose combination antiretroviral medications emtricitabine taf descovy also approved us food drug administration fda preexposure prophylaxis prep indication reduce risk sexually acquired hiv infection certain atrisk patients odefsey oral formulation dosed day treatment hiv infection certain patients odefsey single tablet regimen fixeddose combination antiretroviral medications emtricitabine taf rilpivirine marketed janssen sciences ireland unlimited company one janssen pharmaceutical companies johnson johnson janssen truvada oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients fixed dose combination antiretroviral medications tdf emtricitabine truvada also approved fda prep indication reduce risk sexually acquired hiv infection certain atrisk patients compleraeviplera oral formulation dosed day treatment hiv infection certain patients product marketed united states complera europe eviplera single tablet regimen fixeddose combination antiretroviral medications tenofovir disoproxil fumarate tdf emtricitabine janssens rilpivirine hydrochloride stribild oral formulation dosed day treatment hiv infection certain patients stribild single tablet regimen fixeddose combination antiretroviral medications elvitegravir cobicistat tdf emtricitabine atripla oral formulation indicated complete regimen treatment hiv infection certain patients atripla fixeddose combination antiretroviral medications tdf emtricitabine bristolmyers squibb company bmss efavirenz covid veklury remdesivir injection intravenous use nucleotide analog rna polymerase inhibitor indicated certain patients treatment coronavirus disease covid requiring hospitalization liver diseases epclusa oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir treatment chronic hepatitis c virus hcv infection adults certain pediatric patients genotype without cirrhosis compensated cirrhosis ii decompensated cirrhosis use combination ribavirin addition authorized generic version epclusa distributed separate subsidiary asegua therapeutics llc harvoni oral formulation oncedaily single tablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adults genotype without cirrhosis compensated cirrhosis ii adults genotype infection decompensated cirrhosis combination ribavirin iii adults genotype liver transplant recipients without cirrhosis compensated cirrhosis combination ribavirin iv certain pediatric patients genotype without cirrhosis compensated cirrhosis addition authorized generic version harvoni distributed separate subsidiary asegua therapeutics llc vosevi oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir voxilaprevir retreatment chronic hcv infection adults genotype previously treated nsa inhibitorcontaining regimen ii genotype previously treated sofosbuvircontaining regimen without nsa inhibitor vemlidy oral formulation taf dosed day treatment chronic hepatitis b virus hbv infection adults compensated liver disease viread oral formulation tdf dosed day treatment chronic hbv infection adults certain pediatric patients hematologyoncologycell therapy yescarta axicabtagene ciloleucel suspension intravenous infusion chimeric antigen receptor car cell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy including diffuse large bcell lymphoma dlbcl otherwise specified primary mediastinal large bcell lymphoma highgrade bcell lymphoma dlbcl arising follicular lymphoma tecartus brexucabtagene autoleucel suspension intravenous infusion car cell therapy treatment adult patients relapsed refractory mantle cell lymphoma trodelvy sacituzumab govitecanhziy injection intravenous use trop directed antibody topoisomerase inhibitor conjugate indicated treatment adult patients metastatic triplenegative breast cancer received least two prior therapies metastatic disease indication approved accelerated approval fda continued approval indication may contingent upon verification description clinical benefit confirmatory trials zydelig idelalisib oral formulation kinase inhibitor treatment patients relapsed chronic lymphocytic leukemia cll combination rituximab rituximab alone would considered appropriate therapy due comorbidities ii relapsed follicular bcell non hodgkin lymphoma fl patients received least two prior systemic therapies iii relapsed small lymphocytic lymphoma received least two prior systemic therapies letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsening ii combination tadalafil reduce risks disease progression hospitalization worsening pah improve exercise ability ranexa ranolazine oral formulation extendedrelease tablet antianginal treatment chronic angina ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment serious invasive fungal infections caused various fungal species adults information revenuegenerating products including amount revenue contributed products listed see note revenues notes consolidated financial statements included part ii item annual report revenue share revenues also generate revenues activities including revenue share combination products royalties outbound licenses intellectual property payments received collaborations thirdparty partners example pursuant collaboration janssen receive revenue share cobicistat emtricitabine taf components symtuza darunavircobicistatemtricitabinetaf fixeddose combination product commercialized janssen include revenue share symtuza product sales description collaborations janssen partners see note collaborations arrangements notes consolidated financial statements included part ii item annual report form k commercialization distribution us international commercial sales operations marketing subsidiaries countries products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute products united states exclusively wholesale channel twelve months ended december approximately product sales united states approximately total worldwide revenues three large wholesalers amerisourcebergen corporation cardinal health inc mckesson corporation sell distribute products europe countries outside united states product approved either commercial teams thirdparty distributors corporate partners competition operate highly competitive environment face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers products compete commercially available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing products mature private insurers government payers often reduce amount reimburse patients increases pressure us reduce prices new branded generic products introduced major markets ability maintain pricing market share may affected research development research development rd mission discover develop transformational therapies areas high unmet medical need product development efforts focused primarily viral diseases inflammatory diseases oncology team research scientists engaged discovery development new molecules technologies hope lead approval innovative medicines therapies advance current standard care address unmet medical needs intend continue committing significant resources internal rd opportunities external business development activity drive innovation growth business development product candidates investigational therapies pipeline subject various risks uncertainties risks uncertainties include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain regulatory approvals result product candidates investigational therapies may never successfully commercialized drug development inherently risky many product candidates investigational therapies fail development process continued invest advance rd pipeline across therapeutic areas summary product candidates phase registrational phase clinical trials pending marketing authorization review fda european medicines agency ema product candidates viral diseases product candidates description phase phase remdesivir injection remdesivir injection evaluated outpatient treatment covid expanded indication lenacapavir lenacapavir hiv capsid inhibitor evaluated component longacting regimen treatment hiv infection heavily treatmentexperienced people living hiv granted breakthrough therapy designation fda indication bulevirtide bulevirtide evaluated treatment chronic hepatitis delta virus hdv infection granted orphan drug breakthrough therapy designations fda chronic hdv infection also granted breakthrough therapy designation priority medicines prime scheme eligibility european commission chronic hdv infection december entered definitive agreement acquire myr gmbh upon closing subject regulatory clearances conditions acquisition provide us hepcludex bulevirtide conditionally approved european commission treatment chronic hdv infection july product candidates inflammatory diseases product candidates description regulatory filing filgotinib marketing authorization application filed ema filgotinib jak inhibitor treatment ulcerative colitis phase filgotinib filgotinib evaluated treatment crohns disease cilofexor cilofexor fxr agonist evaluated treatment primary sclerosing cholangitis product candidates oncology product candidates description regulatory filing axicabtagene ciloleucel supplemental biologics license application axicabtagene ciloleucel car cell therapy treatment relapsed refractory indolent nonhodgkins lymphoma inhl filed fda granted breakthrough therapy designation fda inhl indication brexucabtagene autoleucel brexucabtagene autoleucel car cell therapy received accelerated approval fda conditional marketing authorization european commission treatment adult patients relapsed refractory mantle cell lymphoma two lines systemic therapy including brutons tyrosine kinase inhibitor conditional marketing authorization europe initially valid one year extended converted unconditional authorization submission assessment additional confirmatory data sacituzumab govitecanhziy supplemental biologics license application full approval sacituzumab govitecanhziy trop directed antibody topoisomerase inhibitor conjugate treatment patients metastatic triplenegative breast cancer mtnbc received least two prior therapies filed fda granted breakthrough therapy designation fda mtnbc indication sacituzumab govitecanhziy supplemental biologics license application accelerated approval sacituzumab govitecanhziy treatment heavilypretreated patients metastatic urothelial cancer filed fda phase axicabtagene ciloleucel axicabtagene ciloleucel evaluated treatment second line diffuse large b cell lymphoma magrolimab magrolimab anticd evaluated treatment myelodysplastic syndrome mds granted breakthrough therapy designation fda prime scheme eligibility european commission mds indication sacituzumab govitecanhziy sacituzumab govitecanhziy evaluated treatment hormone receptor positive hr human epidermal growth factor receptor negative metastatic breast cancer patients failed least two prior chemotherapy regimens registrational phase brexucabtagene autoleucel brexucabtagene autoleucel car cell therapy evaluated treatment adult acute lymphoblastic leukemia granted breakthrough therapy designation fda adult indication brexucabtagene autoleucel brexucabtagene autoleucel car cell therapy evaluated treatment pediatric granted breakthrough therapy designation fda pediatric indication magrolimab magrolimab evaluated treatment diffuse large b cell lymphoma also seek add portfolio products product candidates acquisitions inlicensing strategic collaborations entered strategic partnerships acquisitions enhance commercial portfolio clinical pipeline across multiple therapeutic areas example acquisition immunomedics inc immunomedics added trodelvy pipeline programs oncology portfolio strategic business development activity reflects commitment focus transformative science build sustainable diverse portfolio position near medium longterm growth business patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents key product candidates described product candidates fixeddose combinations single tablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients single tablet regimen key product candidates patent expiration us eu viral diseases remdesivir lenacapavir bulevirtide inflammatory diseases filgotinib cilofexor oncology axicabtagene ciloleucel brexucabtagene autoleucel sacituzumab govitecanhziy magrolimab december entered definitive agreement acquire myr gmbh upon closing subject regulatory clearances conditions acquisition provide us bulevirtide composition matter patent expired european union european union united states patent applications pending relating proprietary manufacturing processes kite gilead company kite application patent term extension filed united states granted would extend us expiration date least regulatory exclusivity united states expires following table shows actual estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents principal products products fixeddose combinations single tablet regimens estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients single tablet regimen products patent expiration us eu ranexa atripla truvada descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi veklury tecartus trodelvy jyseleca hepcludex estimated expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted gilead lupin limited reached agreement settle patent litigation matter related ranexa gilead teva pharmaceuticals teva reached agreement settle patent litigation concerning patents protect emtricitabine truvada atripla products pursuant teva permitted launch generic fixeddose combinations emtricitabine tdf generic fixeddose combinations emtricitabine tdf efavirenz united states september supplementary protection certificates spcs granted several european countries validity spcs challenged several generic manufacturers many launched competing products applications patent term extensions pending united states andor spcs pending one countries european union products composition matter patent expired european union european union united states patent applications pending relating proprietary manufacturing processes kite gilead mylan pharmaceuticals reached agreement settle patent litigation concerning patents protect cobicistat stribild genvoya products application patent term extension filed united states granted would extend us expiration date least regulatory exclusivity united states expires december entered definitive agreement acquire myr gmbh upon closing subject regulatory clearances conditions acquisition provide us hepcludex bulevirtide conditionally approved european commission treatment chronic hdv infection july bulevirtide approved fda use safety efficacy established patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology patents covering certain active pharmaceutical ingredients api hiv products well cell therapy products held third parties acquired exclusive rights patents agreements parties may obtain patents certain products many years marketing approval obtained patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries example extensions patents supplementary protection certificates many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents third parties infringe valid patents third parties reputation may harmed may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned parties parties may claim cover use sofosbuvir axicabtagene ciloleucel brexucabtagene autoleucel tenofovir disoproxil tenofovir alafenamide bictegravir patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interferencederivation proceedings litigation determine right patent litigation interferencederivation proceedings unpredictable expensive even ultimately successful results operations may adversely affected events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection time time certain individuals entities may challenge patents pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries provide effective enforcement patents thirdparty manufacturers may able sell generic versions products countries description significant pending legal proceedings see note commitments contingencies notes consolidated financial statements included part ii item annual report see also item risk factors success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partners cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected manufacturing raw materials products manufactured either facilities thirdparty contract manufacturers depend third parties perform manufacturing activities majority api drug products products including hiv hcv products use multiple thirdparty contract manufacturers primary backup suppliers manufacturing sites cell therapy products established clinical commercial manufacturing facilities cell processing activities future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale manufacturing facilities lease manufacturing facilities manufacture distribute certain products api clinical andor commercial uses facilities located foster city san dimas la verne oceanside el segundo california morris plains new jersey dublin cork ireland hoofddorp netherlands edmonton canada foster city california conduct process chemistry research formulation development activities manufacture api drug product clinical trials oversee thirdparty contract manufacturers san dimas la verne california manufacture ambisome also package label majority commercial products distribution americas pacific rim oceanside california utilize facility clinical manufacturing process development biologics candidates el segundo california utilize facility clinical commercial manufacturing processing cell therapy products morris plains new jersey utilize facility commercial manufacturing process optimization antibody drug conjugate products cork dublin ireland utilize cork facility commercial manufacturing packaging labeling products also perform quality control testing labeling packaging final release many products cork facility distributed european union international markets facility dublin utilize facility central dublin drug development hub pediatric programs perform clinical development safety quality biostatistics data sciences regulatory compliance functions edmonton canada conduct process chemistry research scaleup activities clinical development candidates manufacture api investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes hoofddorp netherlands utilize facility commercial manufacturing processing cell therapy products thirdparty manufacturers believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict using revealing technology certain thirdparty manufacturers comply restrictions information thirdparty manufacturers see item risk factors may face manufacturing difficulties delays interruptions including thirdparty manufacturers corporate partners regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency similar regulations effect jurisdictions manufacturing operations subject routine inspections regulatory agencies cell therapy products required fda comply risk evaluation mitigation strategy program includes educating certifying medical personnel regarding therapy procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities additionally required maintain complex chain identity custody respect patient material material moves manufacturing facilities manufacturing process back patient access raw materials need access certain raw materials conduct clinical trials manufacture products raw materials generally available multiple sources purchased worldwide normally available quantities adequate meet needs business attempt manage risks associated supply chain inventory management relationship management evaluation alternative sources feasible information see item risk factors may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues human capital gileads success depends work dedicated employees embrace shared sense purpose culture excellence human capital objective make gilead employer choice best talent industry gileads key priorities human capital management include inclusion diversity health safety total rewards employee development engagement boards compensation talent committee oversees overall human capital management inclusion diversity inclusion gilead core value committed advancing inclusion diversity id workforce established global diversity council responsible governance matters tracking progress goals promoting culture inclusion global diversity council chaired chairman chief executive officer gilead implemented multiple programs train managers id topics build awareness drive inclusive behaviors employee resource groups ergs support diverse employees aim raise awareness different cultures within workplace cultivate diversity business strength support gileads talent acquisition strategy source attract recruit diverse candidates believe gileads inclusive diverse workforce foundation innovation productivity gileads commitment equal employment opportunity furthers efforts cultivate celebrate equitable culture belonging december gilead approximately employees gileads global workforce approximately female male additionally women represented gileads leadership defined vice president level us based employees voluntary selfidentification workforce white asian hispanic black health safety gilead committed providing safe healthy secure workplace employees environmental health safety policy maintain various compliance programs support commitment routinely train educate employees workplace safety security due covid pandemic gilead sites required flexible location employees work home employees needed physically present positions laboratory technicians continued work gilead sites implemented site enhancements risk protocols including health screenings covid testing reconfiguration work common spaces allow social distancing effort support safe occupancy sites gilead also maintains robust contact tracing notification process employee reports covid infection date identified cases viral transmission covid workplace total rewards gileads compensation benefits programs designed help attract cultivate retain industrys talented workforce total rewards program varies country includes competitive base salary incentive compensation stock awards employee stock purchase plan k savings plan company match vests immediately health welfare valuable benefits flexible spending accounts paid time family leave family care resources adoption surrogacy assistance employee assistance programs global wellness reimbursement tuition assistance among many others year reassess total rewards package confirm whether offers benefits incentives align total reward philosophy response covid pandemic implemented number temporary covidspecific benefits cost reimbursements essential home office equipment monthly reimbursements childcare homeschooling costs special pay enhancement physical location dependent workers required onsite gilead due nature role support workforce unique challenges presented pandemic committed address pay equity employee salaries informed marketbased ranges assessed annually performance career development reviews policy compensation decisions made without regard personal characteristics gender race color national ethnic origin age disability sexual orientation gender identity expression genetic information religion veteran status also conduct annual pay equity review employee compensation effort strive make pay practices gender race neutral employee development engagement gilead offers number professional management leadership development training programs help employees develop crossfunctional skills tools grow careers addition employees receive reimbursement tuition expenses incurred pursuing undergraduate graduate certificate courses accredited college university make changes pursue ambition becoming employer choice industry important consider input employees listening strategy helps gather employee input measure progress conducted several global surveys assess improve employee retention engagement gather feedback take actions address areas employee concern employee responses surveys key determining meaningful benefits related covid pandemic well direction culture going forward environmental social governance esg gilead also built corporate social responsibility program continue execute mission providing lifesaving medicines areas unmet need additional information program esg highlights available gileads year review gileads website httpswwwgileadcomnews andpressannualreportyearinreview seasonality operations worldwide product sales reflect significant degree seasonality enduser demand however united states fluctuations wholesaler inventory levels impact product sales typically observe strong wholesaler subwholesaler purchases products fourth quarter resulting inventory drawdown wholesalers subwholesalers subsequent first quarter several factors including government budgets annual grant cycles federal state funds covid pandemic buying patterns also could impact product sales recorded particular quarter information see item risk factors face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories government regulation operations activities subject extensive regulation numerous government authorities united states european union countries including laws regulations governing testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming significant impact capital expenditures results operations regulatory requirements applicable drug development approval subject change legal regulatory changes may impact operations future countrys regulatory agency fda united states european medicines agency european commission european union well national authorities european union member states must approve drug sold respective country countries general process drug approval united states summarized many countries including countries european union european union centralized procedure similar regulatory structures preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials phase drug candidate appears effective appropriate safety profile phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data clinical trials show acceptable benefitrisk profile submit appropriate filing usually form new drug application nda biologics license application bla supplemental application fda seeking approval sell drug candidate particular use fdas discretion fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees drug met required level safety efficacy particular use approve application allow us sell drug united states use unusual however fda decline approve application believes drug candidate safe enough efficacious enough ie appropriate benefit versus risk profile believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards concerns safety efficacy uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california also must licensed state california compliance local regulatory requirements manufacturing facilities canada ireland netherlands also must obtain local licenses permits compliance local regulatory requirements fda may employ one several tools facilitate expedite development review drug including fast track designation breakthrough therapy designation accelerated approval priority review designation fast track designation designed facilitate development review drug treats serious condition fills unmet medical need breakthrough therapy designation designed expedite development review drug treats serious condition preliminary clinical evidence demonstrates substantial improvement available therapies accelerated approval drug may granted fda drug treats serious condition fills unmet medical need studied safety efficacy priority review designation means fdas goal take action application within six months filing fda may grant priority review designation drug would provide significant improvement safety effectiveness treatment diagnosis prevention serious condition european union regulatory system approval process european union eu products subject variety eu eu member state regulations governing clinical trials commercial sales distribution required obtain marketing authorization eu market medicinal products relevant market conduct clinical trials eu governed among others directive ec directive ec eu ich good clinical practice rules impose legal regulatory obligations similar provided applicable us laws conduct clinical trials eu must approved competent authorities eu member states clinical trials take place positive opinion must obtained relevant ethics committee relevant member state eu legislator adopted regulation eu replace directive ec introduce coordinated procedure authorization clinical trials regulation expected apply marketing authorization holders manufacturers importers wholesalers distributors medicinal products placed market eu required comply number regulatory requirements including pharmacovigilance good manufacturing practices compliance requirement obtain manufacturing import andor distribution licenses issued competent authorities eu member states failure comply requirements may lead imposition civil criminal administrative sanctions including suspension marketing manufacturing authorizations pricing reimbursement successful commercialization products depends part availability thirdparty payer reimbursement cost products related treatments medical services markets sell products government health authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities private payers increasingly attempting limit regulate price medical products services significant portion sales majority products subject substantial discounts list prices including rebates may required pay medicaid agencies discounts may required pay b covered entities result price increases implement time time certain products may limited effect product sales certain markets addition standard reimbursement structures may adequately reimburse innovative therapies products mature private insurers government payers often reduce amount reimburse providers increases pressure us reduce prices new branded generic products introduced major markets ability maintain pricing market share may affected information see item risk factors existing products subject reimbursement pressures government agencies third parties required rebates discounts products pricing pressures face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories patient assistance programs recently enhanced scrutiny companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement support offerings clinical education programs promotional speaker programs agents vendors deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products health care fraud abuse laws antibribery laws subject various us federal state laws pertaining health care fraud abuse including antikickback laws false claim laws anti kickback laws make illegal prescription drug manufacturer knowingly willingly solicit offer receive pay remuneration exchange induce referral business reimbursed federal healthcare program including purchase prescription particular drug false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim due breadth statutory provisions attention given law enforcement authorities sales marketing patient support medical activities may subject scrutiny laws example recently enhanced scrutiny government enforcement authorities companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance reimbursement support offerings clinical education programs promotional speaker programs similarly europe interactions pharmaceutical companies physicians subject strict laws regulations industry selfregulation codes conduct physicians codes professional conduct applicable including eu member states anticorruption laws uk bribery act addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us unlawful acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program similar violations competitors could also negatively impact reputation industry increase governmental public scrutiny business products us healthcare reform us federal state governments continue propose pass legislation designed regulate healthcare industry including legislation seeks indirectly directly regulate pharmaceutical drug pricing information see item risk factors impacted evolving laws regulations legislative regulatory actions applicable health care industry environment subject number laws regulations require compliance federal state local regulations protection environment regulatory landscape continues evolve anticipate additional regulations future laws regulations implemented consideration mitigate effects climate change mainly caused greenhouse gas emissions business energy intensive therefore anticipate subject cap trade system mitigation measure would materially impact capital expenditures operations competitive position information subject information requirements securities exchange act exchange act therefore file periodic reports proxy information statements information sec sec maintains website httpwwwsecgov contains reports proxy information statements information regarding issuers file electronically sec mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors website sec filings section make available following filings free charge soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act website references provided throughout document convenience content referenced websites constitute part incorporated reference annual report item risk factors evaluating business carefully consider following discussion material risks events uncertainties make investment us speculative risky addition information annual report manifestation following risks uncertainties could circumstances may may able accurately predict materially adversely affect business growth reputation including commercial scientific reputation products prospects product pipeline sales operating financial results financial condition cash flows liquidity stock price note factors investors permitted private securities litigation reform act possible predict identify factors operations could also affected factors events uncertainties presently known us currently consider present significant risks operations therefore consider following risks complete statement potential risks uncertainties face product commercialization risks certain products subject us additional heightened risks hiv products receive substantial portion revenue sales products treatment prevention hiv infection twelve months ended december sales hiv products accounted approximately total product sales may unable sustain increase sales hiv products number reasons including market share gains competitive products inability introduce new hiv medications necessary remain competitive case may need scale back operations including future drug development spending research development rd efforts example hiv products contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf andor emtricitabine ftc belong nucleoside class antiviral therapeutics changes treatment paradigm hiv may cause nucleosidebased therapeutics fall favor veklury remdesivir face risks related significant investment rapid development manufacturing distribution veklury remdesivir approved us food drug administration fda october treatment hospitalized patients covid given severity urgency covid pandemic committed significant capital resources clinical trials scaleup production remdesivir expect investment continue beyond continue manufacture large quantities finished product conduct additional studies specific patient populations develop evaluate new formulations delivery methods combinations therapies utilization remdesivir largely tracked level infections unable accurately predict revenues supply needs short long term due potential new better therapeutics availability effectiveness vaccines fluctuating hospital utilization rates unable accurately forecast demand manufacture veklury levels meet actual demand may result shortages excess inventory may written subject significant public attention scrutiny complex decisions made regarding clinical data allocation distribution pricing veklury affects corporate reputation yescarta advancing novel personalized therapy yescarta chimeric antigen receptor car cell therapy creates significant challenges including educating certifying medical personnel regarding procedures potential side effects cytokine release syndrome neurologic toxicities compliance risk evaluation mitigation strategy program required fda securing sufficient supply medications manage side effects tocilizumab corticosteroids may available sufficient quantities may adequately control side effects andor may detrimental impacts efficacy yescarta developing maintaining robust reliable process engineering patients cells facilities infusing back patient conditioning patients chemotherapy advance administering therapy may increase risk adverse side effects use engineered cells potential cancer treatment recent development may broadly accepted physicians patients hospitals cancer treatment centers payers others medical community may able demonstrate medical community payers potential advantages yescarta compared existing future therapeutics challenges related reimbursement yescarta see also existing products subject reimbursement pressures government agencies third parties required rebates discounts products pricing pressures rely thirdparty sites collect patients white blood cells known apheresis centers well shippers couriers hospitals logistical collection patients white blood cells ultimate delivery yescarta patients vendors may encounter disruptions difficulties could result product loss regulatory action apheresis centers may also choose participate quality certification process may unable complete certification timely manner could delay constrain manufacturing commercialization efforts success depends developing commercializing new products expanding indications existing products unable launch commercially successful new products new indications existing products business adversely impacted launch commercially successful products necessary grow business cover substantial rd expenses offset revenue losses existing products lose market share due factors competition loss patent exclusivity many difficulties uncertainties inherent drug development introduction new products product development cycle characterized significant investments resources long lead times unpredictable outcomes due nature developing medicines human use expend significant time resources product pipeline without assurance recoup investments efforts commercially successful high rate failure inherent discovery development new products failure occur point process including late process substantial investment face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories may unable accurately predict demand products including uptake new products demand depends number factors example product demand may adversely affected physicians see benefit products additionally nonretail sector united states includes government institutions including state aids drug assistance programs us department veterans affairs correctional facilities large health maintenance organizations tends less consistent terms buying patterns often causes quarteroverquarter fluctuations necessarily mirror patient demand products federal state budget pressures well annual grant cycles federal state funds may cause purchasing patterns reflect patient demand products expect continue experience fluctuations purchasing patterns nonretail customers light budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels may continue see trend future sell distribute products united states exclusively wholesale channel year ended december approximately product sales united states three wholesalers amerisourcebergen corporation cardinal health inc mckesson corporation us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesaler locations inventory management agreements control buying patterns adverse changes economic conditions increased competition factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even end user demand changed addition observed strong wholesaler subwholesaler purchases products fourth quarter typically results inventory drawdown wholesalers subwholesalers subsequent first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers new branded generic products entering major markets affects ability maintain pricing market share products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing number companies pursuing development technologies competitive existing products research programs competing companies include large pharmaceutical biotechnology companies specialized pharmaceutical firms acting either independently together companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs may adversely impacted competitors gain market share result new technologies commercialization strategies otherwise existing products subject reimbursement pressures government agencies third parties required rebates discounts products pricing pressures product reimbursements successful commercialization products depends part availability thirdparty payer reimbursement cost products related treatments medical services markets sell products government health authorities private health insurers organizations generally provide reimbursement products mature private insurers government payers often reduce amount reimburse patients products increases pressure us reduce prices legislative regulatory actions affecting government prescription drug procurement reimbursement programs occur relatively frequently example september fda issued final rule implementing pathway importation certain prescription drugs canada rule subject ongoing litigation addition november centers medicare medicaid services cms issued interim final rule would substantially alter medicare part b reimbursement system physicianadministered medicines january rule subject ongoing litigation cms preliminarily enjoined implementing rule may adversely impacted legislative regulatory actions though difficult predict impact use reimbursement products product pricing discounts rebates united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services united states volume drug pricingrelated bills dramatically increased recent years example congress proposed bills change medicare part benefit impose inflation based rebate list prices drugs grow faster inflation increase manufacturer contributions benefit phases addition many state legislatures considering already passed law legislation seeks indirectly directly regulate pharmaceutical drug pricing requiring manufacturers publicly report proprietary pricing information creating review boards prices state agencies encouraging use generic drugs initiatives legislation may cause added pricing pressures products resulting impact business uncertain many countries outside united states including european union member states established complex lengthy procedures obtain price approvals coverage reimbursement periodically review pricing reimbursement decisions outcome review predicted could adverse effect pricing reimbursement medicinal products european union member states reductions pricing medicinal products one member state could affect price member states negative impact financial results substantial portion product sales subject significant discounts list price including rebates may required pay state medicaid agencies discounts provided b covered entities changes b program medicaid program federal state level could material adverse effect business example december cms issued final rule make certain changes calculation rebates medicaid drug rebate program among changes effective january final rule change requirements excluding manufacturer copay coupons medicaid best price changes go effect could substantially increase medicaid rebate obligations decrease prices charge b covered entities continued growth b program also limits prices may charge increasing number customers addition standard reimbursement structures may adequately reimburse innovative therapies example beginning fiscal year cms established new severity adjusted diagnosis related group drg medicare inpatient reimbursement car products yescarta tecartus new drg significantly higher base payment amount prior drg payment available may sufficient reimburse hospitals cost care patients receiving yescarta tecartus reimbursement aligned well account treatment costs medicare beneficiaries may denied access misalignment could impact willingness hospitals offer therapy doctors recommend therapy additionally european union barriers reimbursement individual countries could limit uptake yescarta tecartus addition estimate rebates required pay connection sales particular quarter based claims data prior quarters united states actual rebate claims typically made payers one three quarters arrears actual claims payments may vary significantly estimates may experience adverse impacts resulting imports countries products available lower prices imports unapproved generic counterfeit versions products prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported resold countries lower price markets example us sales could also affected fda permits importation drugs canada entered agreements generic drug manufacturers well licensing agreements medicines patent pool united nationsbacked public health organization allows generic drug manufacturers manufacture generic versions certain products distribution certain low middleincome countries may adversely affected generic versions products whether produced andor distributed agreements exported united states europe markets higher prices european union required permit products purchased one european union member state sold another member state purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter additionally diverted products may used countries approved patients may source diverted products outside legitimate supply chain diverted products may handled shipped stored inappropriately may affect efficacy products could harm patients adversely impact us also aware existence various buyers clubs around world promote personal importation generic versions products approved use countries imported result patients may risk taking unapproved medications may purport may potency claim may contain harmful substances could adversely impact us third parties may illegally distribute sell counterfeit versions medicines meet rigorous quality standards manufacturing supply chain counterfeit medicines pose serious risk patient health safety may raise risk product recalls actions discourage distribution sale counterfeit versions medicines around world may successful may adversely affected result product development supply chain risks face risks clinical trials including potential unfavorable results delays anticipated timelines disruption required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted addition may also face challenges clinical trial protocol design may adversely impacted clinical trials product candidates pipeline delayed terminated face numerous risks uncertainties product candidates could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory agency approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline key anticipated milestones product candidates include among others phase data readouts sacituzumab govitecanhziy treatment hormone receptor positive human epidermal growth factor receptor negative metastatic breast cancer patients axicabtagene ciloleucel treatment second line diffuse large b cell lymphoma may adversely impacted favorable results studies programs pipeline completed timely basis addition clinical trials involving commercial products could raise new safety issues existing products addition extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent thirdparty contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management patient enrollment ongoing monitoring site management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals may adversely affected may face manufacturing difficulties delays interruptions including thirdparty manufacturers corporate partners products manufactured facilities thirdparty manufacturers corporate partners result complex highly regulated manufacturing processes depend thirdparty manufacturers corporate partners perform manufacturing activities effectively timely basis majority active pharmaceutical ingredients drug products third parties independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners subject good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency ema well comparable regulations jurisdictions manufacturing operations also subject routine inspections regulatory agencies adverse developments affecting resulting manufacturing operations operations thirdparty manufacturers corporate partners may result shipment delays inventory shortages lot failures product withdrawals recalls interruptions commercial supply products may also need take inventory writeoffs incur charges expenses products fail meet specifications quality standards undertake costly remediation efforts seek costly manufacturing alternatives developments could increase manufacturing costs cause us lose revenues market share damage reputation addition manufacturing issues may cause delays clinical trials applications regulatory approval example unable remedy deficiencies cited fda regulatory agencies inspections currently marketed products timing regulatory approval product candidates development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries business may adversely affected approval product candidates delayed production products interrupted may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues need access certain supplies products conduct clinical trials manufacture sell products unable purchase sufficient quantities materials find suitable alternative materials timely manner development efforts product candidates may delayed ability manufacture products could limited suppliers key components materials must named new drug application marketing authorization application filed regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control maintain full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand addition deliveries materials suppliers interrupted reason may unable ship certain products commercial supply supply product candidates development clinical trials also products materials utilize operations manufactured one facility may able replace timely manner commercially reasonable terms problems single suppliers depend including event disaster earthquake equipment failure difficulty may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture antiviral products supplied thirdparty manufacturers corporate partners outside united states result political economic factors specific country region including changes interpretations trade regulations compliance requirements tax legislation would limit prevent third parties outside united states supplying materials could adversely affect ability manufacture supply antiviral products meet market needs material adverse effect operating results encounter difficulties ability conduct clinical trials product candidates manufacture sell products could impaired regulatory legal risks operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda ema comparable regulatory agencies countries filed anticipate file marketing approval additional countries additional indications products next several years future marketing applications file may approved regulatory authorities timely basis even marketing approval granted products may significant limitations use state certainty whether product candidates development approved launched whether able develop license acquire additional product candidates products whether products launched commercially successful manufacture sell products subject extensive regulation review example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk certain circumstances may required implement risk evaluation mitigation strategy program products could include medication guide patient package insert communication plan healthcare providers restrictions distribution use product elements fda deems necessary assure safe use drug discovery previously unknown problems marketed products product candidates including serious safety resistance drug interaction issues problems manufacturing safety reporting promotional activities may result regulatory approvals delayed denied granted significant restrictions products including limitations withdrawal products market failure comply requirements imposed fda could result significant civil monetary penalties fines suspensions regulatory approvals product recalls seizure products criminal prosecutions impacted evolving laws regulations legislative regulatory actions applicable health care industry health care industry subject various federal state international laws regulations pertaining drug reimbursement rebates price reporting health care fraud abuse data privacy security united states laws include antikickback false claims laws laws regulations relating medicare medicaid programs federal state programs medicaid rebate statute individual state laws relating pricing sales marketing practices health insurance portability accountability act federal state laws relating privacy security health information actual alleged violations laws related regulations may punishable criminal andor civil sanctions including instances substantial fines civil monetary penalties exclusion participation federal state health care programs including medicare medicaid department veterans affairs department defense health programs actions executives overseeing business significant remediation measures negative publicity consequences laws regulations broad scope subject changing evolving interpretations could require us incur substantial costs associated compliance alter one sales marketing practices example united states challenge affordable care act aca currently pending us supreme court resulted uncertainty regarding acas future viability destabilization health insurance market resulting impact business uncertain could material addition government price reporting payment regulations complex continually assessing methods calculate report pricing accordance obligations methodologies calculations inherently subjective may subject review challenge various government agencies may disagree interpretation government disagrees reported calculations may need restate previously reported data could subject additional financial legal liability also continues enhanced scrutiny companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement support offerings clinical education programs promotional speaker programs agents vendors deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products description government investigations related litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report subject risks significant safety issues arise marketed products product candidates additional studies conducted subsequent obtaining marketing approval products products used longer periods time many patients including patients underlying health problems patients taking medicines expect continue finding new issues related safety resistance drug interactions issues may require changes product labels additional warnings contraindications even narrowed indications halt sales product regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information clinical trial data directly available public websites means periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties patents proprietary rights important business part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology success depends significant degree ability obtain patents licenses patent rights preserve trade secrets internal knowhow defend infringement patents efforts invalidate operate without infringing intellectual property others since patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors file patent applications covering technology may participate litigation postgrant proceedings us patent trademark office proceedings determine right patent validity patent granted litigation proceedings unpredictable expensive could divert management attention operations even ultimately successful may adversely impacted generic manufacturers sought may continue seek fda approval market generic versions products abbreviated new drug application anda application process typically used manufacturers seeking approval generic drug description anda litigation see commitments contingencies notes consolidated financial statements included part ii item annual report entry generic versions products may future lead market share price erosion found infringe valid patents third parties may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license commercially reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products aware patents patent applications owned third parties parties may claim cover use sofosbuvir axicabtagene ciloleucel bictegravir example february viiv filed lawsuit us us district court delaware alleging commercialization bictegravir sold commercially combination taf ftc biktarvy infringes viivs us patent patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claims patent court set trial date january lawsuit viiv seeking billions dollars alleged damages comprised viivs lost profits royalty sales bictegravir launch trial addition court find liable infringement expect viiv seek royalty sales trial viiv calculates damages based cumulative us revenues biktarvy since launch totaled billion december although predict certainty ultimate outcome litigation adverse judgment could result substantial monetary damages including viivs lost profits royalties trial goingforward royalty stream future sales see description litigation related matters note commitments contingencies notes consolidated financial statements included part ii item annual report furthermore also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions could adversely affected trade secrets internal know technological innovation confidential information become known independently discovered competitors enter disputes ownership inventions face potentially significant liability increased expenses litigation government investigations relating products operations involved number litigation investigation disputerelated matters require us expend substantial internal financial resources including ongoing litigation related yescarta biktarvy products ongoing product liability litigation related tdf products matters could require us pay significant monetary damages including royalty payments past future sales expect matters continue require high level internal financial resources foreseeable future matters reduced expected continue reduce earnings require significant management attention addition testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others limited insurance product liabilities may arise claims may exceed coverage description litigation investigations disputerelated matters see note commitments contingencies notes consolidated financial statements included part ii item annual report outcome legal proceedings legal proceedings may brought us investigations investigations may initiated disputerelated matters inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us operational risks business may future adversely affected outbreaks epidemic pandemic contagious diseases including recent covid outbreak actual threatened outbreaks epidemic pandemic contagious diseases covid may significantly disrupt global operations adversely affect business financial condition results operations example covid pandemic caused significant volatility uncertainty us international markets resulted increased risks operations addition developments discussed part ii item management 's discussion analysis financial condition results operations monitoring number risks related pandemic including following supply chain pandemic could result disruptions supply chain distribution future example quarantines shelterinplace governmental orders policies travel restrictions airline capacity route reductions safety guidelines health impacts pandemic could impact availability productivity products personnel manufacturers distributors freight carriers necessary components supply chain addition may unfavorable changes availability cost raw materials intermediates materials necessary production may result higher costs disruptions supply chain interruptions distribution capabilities clinical trials pandemic adversely affected may continue adversely affect certain clinical trials including ability initiate complete clinical trials within anticipated timelines ongoing trials clinical trial sites imposed restrictions patient visits limit risks possible covid exposure may experience issues participant compliance clinical trial protocols result quarantines travel restrictions interruptions healthcare services also risk closures clinical sites may necessary pandemic related guidance restrictions continue evolve foregoing reasons experienced delays new subject enrollment clinical trials may continue experience overall delays clinical trials also risk biased data collection certain clinical trial sites remain open result challenges anticipated filing marketing timelines certain products may adversely impacted regulatory reviews operations fda ema regulatory agencies may adversely affected may also experience delays necessary interactions regulatory authorities around world including respect anticipated filing together factors resulting pandemic may adversely impact ability launch new commercial products patient access pandemic limited patients ability willingness access seek care healthcare providers initiate new therapies resulted lower demand products particularly respect hiv prevention hepatitis c virus hcv treatment example seen reduction prescription refills hiv prevention result higher discontinuations addition rising unemployment experienced shift payer mix towards governmentfunded coverage uninsured segment employees face risks related health safety morale productivity employees including safe occupancy sites pandemic currently gilead sites requiring flexible location employees work home physical location dependent workers mixed location workers continue work gilead sites job site enhancements risk protocols include health screenings covid testing guarantee maintain continued safe occupancy sites onsite employees testing positive covid could lead mandatory quarantines potential site shutdowns office locations manufacturing plants financial pandemic may continue adverse financial impact shortterm potentially beyond result reduced patient access shift payer mix hcv treatment hiv businesses adversely impacted example product sales excluding veklury fourth quarter full year decreased respectively compared periods due part continued effects pandemic hcv hiv franchises may continue experience fluctuating revenues businesses infection rates rise fall shelter place restrictions periodically tightened eased also experienced may continue experience volatility shortterm revenues due fluctuations inventory channel purchases pandemic could also additional unexpected expenses related pandemic could negatively affect results operations factors together overall uncertainty disruption caused pandemic could result increased volatility decreased predictability results operations volatility stock price pandemic may also amplify many risks described throughout risk factors section annual report extent pandemic impacts business results depend future developments uncertain predicted confidence including potential future waves pandemic new variants virus impact severity duration pandemic development distribution effectiveness public acceptance vaccines ongoing future actions taken contain pandemic face risks associated global operations global operations accompanied certain financial political economic risks including listed foreign currency exchange year ended december approximately product sales outside united states significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar hedging program eliminate exposure currency fluctuations may adversely impacted us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation antibribery subject us foreign corrupt practices act similar worldwide antibribery laws govern international operations respect payments government officials international operations heavily regulated require significant interaction foreign officials operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom possible certain practices may challenged laws addition internal control policies procedures may protect us reckless criminal acts committed employees agents enforcement activities antibribery laws could subject us administrative legal proceedings actions could result civil criminal sanctions including monetary penalties exclusion healthcare programs risks inherent conducting global business include restrictive government actions intellectual property foreign assets nationalization expropriation imposition compulsory licenses protective economic policies taken foreign governments trade protection measures import export licensing requirements may result imposition trade sanctions similar restrictions united states governments business interruptions stemming natural manmade disasters climate change earthquakes hurricanes flooding fires actual threatened public health emergencies efforts taken third parties prevent mitigate disasters public safety power shutoffs facility shutdowns may uninsured inadequately insured example corporate headquarters foster city certain rd manufacturing facilities located california seismically active region event major earthquake may carry adequate earthquake insurance significant recovery time could required resume operations political instability disruption geographic region operate regardless cause including war terrorism social unrest political changes example january united kingdom withdrew european union initiated transition period united kingdom european union negotiate future relationship uncertainty concerning changes laws regulations governing conduct clinical trials marketing medicinal products united kingdom following countrys exit european union uncertainty may lead significant complexity risks company ability research develop market medicinal products european union united kingdom depend relationships third parties sales marketing performance technology development logistics commercialization products failure maintain relationships poor performance companies disputes third parties could negatively impact business rely number collaborative relationships third parties sales marketing performance certain territories example collaboration arrangements janssen sciences ireland uc odefsey compleraeviplera symtuza countries rely international distributors sales certain products relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline due specialized technical nature business failure attract develop retain highly qualified personnel could adversely impact us future success depend large part continued ability attract develop retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization ability also depends part well maintain strong workplace culture attractive employees addition competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit face competition personnel companies universities public private research institutions government entities organizations additionally changes us immigration work authorization laws regulations could make difficult employees work transfer one jurisdictions operate dependent information technology systems infrastructure data may subject cyberattacks security breaches legal claims dependent upon information technology systems infrastructure data including kite konnect platform critical maintain chain identity chain custody yescarta multitude complexity computer systems make inherently vulnerable service interruption destruction malicious intrusion random attack likewise data privacy security breaches employees others pose risk sensitive data including intellectual property trade secrets personal information employees patients customers business partners may exposed unauthorized persons public cyberattacks increasing frequency sophistication intensity including pandemic cyberattacks include example deployment harmful malware denialofservice social engineering means affect service reliability threaten data confidentiality integrity availability business technology partners face similar risks security breach systems could adversely affect security posture assurance efforts efforts partners vendors invest protection information technology infrastructure data prevent future service interruptions identify breaches systems interruptions breaches could cause loss critical sensitive information including personal information addition insurance may sufficient type amount cover losses may result interruption breach systems regulators globally also imposing new data privacy security requirements including new greater monetary fines privacy violations example general data protection regulation gdpr became effective europe established regulations regarding handling personal data non compliance gdpr may result monetary penalties four percent worldwide revenue addition new domestic data privacy security laws california consumer privacy act ccpa became effective january others may passed similarly introduce requirements respect personal information noncompliance ccpa may result liability private actions subject statutorily defined damages event certain data breaches enforcement gdpr ccpa changes new laws regulations associated enhanced protection personal information including cases healthcare data personal information could greatly increase cost providing products services even prevent us offering certain services jurisdictions operate strategic financial risks subject risks associated engaging business acquisitions licensing arrangements collaborations options equity investments asset divestitures strategic transactions engaged may future engage transactions part business strategy may identify suitable transactions future may complete transactions timely manner costeffective basis may realize expected benefits successful making acquisition closing licensing arrangement collaboration products intellectual property technologies acquired licensed may successful may require significantly greater resources investments anticipated part annual impairment testing goodwill indefinitelived intangible assets fourth quarter earlier impairment indicators exist required us generally accepted accounting principles may need recognize impairment charges products intellectual property technologies acquired licensed successful option structured deals assurance elect exercise option right possible disagreements uncertainties circumstances may arise including respect whether option rights appropriately triggered may hinder ability realize expected benefits equity investments strategic transactions connection collaboration galapagos nv value equity investments may fluctuate decline value successful execution implementation transactions financial condition cash flows results operations may adversely affected stock price could decline paid substantial amounts cash incurred additional debt finance strategic transactions additional indebtedness lower cash balance could result downgrade credit ratings limit ability borrow additional funds refinance existing debt favorable terms increase vulnerability adverse economic industry conditions reduce financial flexibility continue capital investments stock repurchases dividend payments example result cash used debt issued connection acquisition immunomedics sp downgraded credit rating may adversely impacted failure overcome additional risks changes effective income tax rate could reduce earnings subject income taxes tax return audits united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering made changes existing tax laws predict form timing changes differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions may adversely affected resolution one exposures reporting period addition significant judgment required determining worldwide provision income taxes various factors may favorable unfavorable effects income tax rate including limited portion nondeductible annual branded prescription drug fee accounting stock options sharebased awards mergersacquisitions restructurings ability maintain manufacturing operational activities irish facilities changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant item b unresolved staff comments applicable item properties corporate headquarters located foster city california house administrative certain rd activities also rd facilities emeryville oceanside santa monica california gaithersburg maryland seattle washington morris plains new jersey edmonton canada dublin ireland principal manufacturing facilities el segundo la verne oceanside san dimas california morris plains new jersey edmonton canada cork ireland hoofddorp netherlands information manufacturing facilities see item business manufacturing facilities global operations include offices europe north america asia south america africa australia middle east believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings description significant pending legal proceedings please see note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report item mine safety disclosures applicable part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild february approximately stockholders record common stock performance graph following graph compares cumulative total stockholder return past five years two indices standard poors stock index sp index nasdaq biotechnology index nbi index stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december assuming dividends reinvested equity compensation plan information following table provides certain information respect equity compensation plans effect december number common shares remaining available future number common shares weightedaverage issuance equity issued upon exercise exercise price compensation plans outstanding options warrants outstanding options excluding securities millions except per share amounts rights warrants rights reflected column plan category b c equity compensation plans approved security holders equity incentive plan employee stock purchase plan total equity compensation plans approved security holders equity compensation plans approved security holders total take account million restricted stock units performance share awards units phantom shares exercise price granted equity incentive plans includes awards shares previously issuable immunomedics inc amended restated longterm incentive plan immunomedics plan assumed connection acquisition immunomedics inc subsequently merged equity incentive plan employee stock purchase plan participants permitted purchase common stock discount certain dates payroll deductions within predetermined purchase period accordingly numbers determinable includes awards shares issuable forty seven inc equity incentive plan assumed connection acquisition forty seven inc forty seven subsequently amended restated equity incentive plan material features gilead sciences inc equity incentive plan forty seven inc equity incentive plan originally established forty seven june connection gileads acquisition forty seven april gilead assumed forty seven inc equity incentive plan amended restated gilead sciences inc equity incentive plan plan plan intended help company secure retain services eligible award recipients provide incentives persons exert maximum efforts success company affiliate provide means eligible recipients may benefit increases value gilead common stock april employees consultants forty seven immediately prior date employees consultants gilead hired following date eligible receive grants new awards plan plan provides award incentive stock options nonstatutory stock options must generally exercise price equal least fair market value common stock date grant stock appreciation rights restricted stock awards restricted stock unit awards performance stock awards stock awards performance cash awards april aggregate number shares common stock issuable plan date april gilead granted restricted stock units stock options plan types equity awards outstanding plan december million shares gilead common stock remained available issuance plan issuer purchases equity securities first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions made repurchases program starting april first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions repurchased retired million shares common stock billion open market transactions program december remaining authorized repurchase amount programs billion table summarizes stock repurchase activity three months ended december maximum fair total number value shares total number average shares purchased may yet shares price paid part publicly purchased purchased per share announced program programs thousands dollars thousands millions october october november november december december total total thousand shares transferred us employees satisfaction minimum tax withholding obligations associated vesting restricted stock units period purchase shares common stock open market pursuant repurchase program item selected financial data gilead sciences inc selected consolidated financial data year ended december millions except per share amounts consolidated statement income data total revenues total costs expenses income operations income tax expense benefit net income net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculation basic net income per share attributable gilead common stockholders diluted shares used per share calculation diluted cash dividends declared per share december millions consolidated balance sheet data cash cash equivalents marketable debt securities working capital total assets longterm obligations longterm debt including current portion retained earnings total stockholders equity see managements discussion analysis financial condition results operations included item annual report description results operations recorded acquired inprocess research development iprd expenses billion primarily related acquisition forty seven inc forty seven well collaborations investments entered year recorded acquired iprd expenses billion primarily due billion upfront collaboration licensing expenses related global research development collaboration galapagos nv pretax impairment charge million assets obtained acquisition kite pharma inc kite recorded discrete tax benefits million related settlements taxing authorities recorded deferred tax benefit billion related intangible asset transfers foreign subsidiary ireland united states recorded deferred tax charge million related transfer acquired intangible assets foreign subsidiary united states december recorded estimated billion net charge related enactment tax cuts jobs act tax reform tax reform also lowered corporate tax rate united states effective tax years beginning december connection acquisition immunomedics issued billion principal amount senior unsecured notes borrowed aggregate principal amount billion threeyear term loan facility also repaid billion principal amount senior unsecured notes maturity repaid billion principal amount senior unsecured notes maturity repaid billion principal amount senior unsecured notes maturity repaid billion term loans borrowed connection acquisition kite connection acquisition kite issued billion aggregate principal amount senior unsecured notes borrowed billion aggregate principal amount term loan facility credit agreement billion repaid issued billion principal amount senior unsecured notes repaid million principal balance convertible senior notes million principal balance senior unsecured notes maturity see note debt credit facilities notes consolidated financial statements included item annual report additional information made cash payments billion primarily related acquisitions immunomedics october forty seven april see note acquisitions notes consolidated financial statements included item annual report additional information item managements discussion analysis financial condition results operations following managements discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures part item risk factors additional information related comparison results operations years included item managements discussion analysis financial condition results operations filed us securities exchange commission sec incorporated reference annual report consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview gilead sciences inc gilead us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis cancer operate countries worldwide headquarters foster city california portfolio marketed products includes ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepsera jyseleca letairis odefsey ranexa sovaldi stribild tecartustm trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status jyseleca varies worldwide jyseleca approved united states also sell distribute authorized generic versions epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain products corporate partners collaborative agreements business highlights financial performance strong despite global impact covid pandemic clear reflection solid underlying fundamentals business driven hiv franchise increased demand saw veklury amid covid pandemic also continued expand strengthen commercial portfolio clinical pipeline across various therapeutic areas drive future growth potential april acquired forty seven inc forty seven approximately billion gaining investigational drug candidate magrolimab currently phase clinical studies number hematological cancers including myelodysplastic syndrome acute myeloid leukemia nonhodgkin lymphoma solid tumors october acquired immunomedics inc immunomedics approximately billion gained trodelvy tropdirected antibodydrug conjugate granted accelerated approval us food drug administration fda treatment adult patients metastatic triplenegative breast cancer mtnbc trodelvy potential broader applicability multiple tumor types studied monotherapy combination agent additional tumor types including hrher breast cancer urothelial cancer nonsmall cell lung cancer solid tumors december entered definitive agreement acquire myr gmbh upon closing subject regulatory clearances conditions acquisition provide us hepcludex bulevirtide conditionally approved european medicines agency ema treatment chronic hepatitis delta virus hdv july significantly expanded oncology portfolio licensing strategic collaboration well equity investments thirdparty collaboration partners additional information included note collaborations arrangements notes consolidated financial statements included item annual report addition assets acquired pursuant strategic transactions developed several therapies treatments portfolio jyseleca tecartus veklury first fdaapproved antiviral therapy covid efforts demonstrate continued commitment advancing innovative medicines areas unmet need key product pipeline corporate updates category therapeutic area description regulatory approval viral diseases submission fda european commission ec japanese ministry health labour welfare jmhlw granted full approval conditional marketing authorization regulatory approval respectively veklury treatment patients covid fda approved supplemental new drug application epclusa treatment children ages older weighing least kg hepatitis c virus hcv oncology fda ec granted accelerated approval conditional marketing authorization respectively tecartus treatment adult patients relapsed refractory mantle cell lymphoma submitted supplemental biologics license application sbla fda approval trodelvy treatment adult patients mtnbc based overall efficacy safety results phase ascent trial kite pharma inc kite submitted sbla fda yescarta treatment relapsed refractory indolent non hodgkins lymphoma kite also received ema approval implement variation yescarta marketing authorization endtoend manufacturing fda granted breakthrough therapy designation magrolimab firstinclass investigational monoclonal antibody treatment newly diagnosed myelodysplastic syndrome inflammatory diseases ema validated reviewing application gilead galapagos nv galapagos new indication approved license filgotinib mg proposed indication treatment adults moderately severely active ulcerative colitis jmhlw ec granted regulatory approval marketing authorization jyseleca respectively treatment adults moderate severe active rheumatoid arthritis corporate development viral diseases gilead vir biotechnology inc established clinical collaboration related hepatitis b virus january gilead gritstone oncology inc announced companies entered collaboration option license agreement related curative treatment hiv february veklury distribution beginning october started distributing veklury united states upon conclusion previous distribution agreement us federal government gilead european union signed joint procurement agreement covers purchases veklury sixmonth period april option extended parties additional sixmonth periods board appointments jeffrey bluestone phd president chief executive officer ceo sonoma biotherapeutics sandra j horning retired chief medical officer global head product development roche javier j rodriguez ceo davita inc anthony welters retired senior advisor office ceo unitedhealth group inc community support february announced new partnership wake forest university school divinity part ongoing compass initiative help mitigate hiv epidemic southern united states launched racial equity community impact fund initially provide million grants organizations working community advocacy mobilization social justice educational innovation covid donated million individual doses remdesivir free charge made various donations support current nonprofit grantees global gilead covid acute relief emergency support grantee fund also made donations san mateo strong fund mayors fund los angeles announced discussed updates detail press releases available website httpswwwgileadcomnewsandpresspressroompressreleases additional information found disclosures filed furnished sec including current reports form k quarterly reports form q applicable readers also encouraged review press releases available website mentioned financial highlights millions except percentages per share amounts change change total revenues net income attributable gilead diluted earnings per share compared total revenues increased billion compared billion primarily due veklury sales higher product sales hiv products including continued patient uptake biktarvy growth descovy preexposure prophylaxis prep increase partially offset lower sales volume truvada emtricitabine ftc tenofovir disoproxil fumarate tdfbased products primarily due loss exclusivity truvada atripla united states october lower sales hcv products due impact covid pandemic expected declines sales letairis ranexa generic entries first half net income attributable gilead million per diluted share compared billion per diluted share primarily due unfavorable changes fair value equity investments galapagos billion discrete tax benefit recorded related intraentity transfers intangible assets different tax jurisdictions higher acquired inprocess research development iprd expenses related acquisition forty seven collaborations investments entered year well higher acquisitionrelated expenses strategy outlook purpose deliver lifechanging medications patients need scientific breakthroughs innovation strong operational execution strategic ambitions bring transformative therapies patients ii biotech employer partner choice iii deliver shareholder value sustainable responsible manner strategic priorities reflect deliver ambitions expand internal external innovation ii strengthen portfolio strategy decision making iii increase patient benefit access iv continue evolve culture continue focus executing strategy expand strengthen commercial portfolio clinical pipelines new therapeutic areas including oncology inflammation maintaining leadership antiviral medications continued growth biktarvy development lenacapavir expansion viral hepatitis business ongoing efforts develop safe effective antivirals patients suffering viral infections beyond expanding products pipeline also continue focus employees evolution culture efforts promote racial equity covid pandemic continues impact business broader market dynamics expect gradual recovery underlying market dynamics starting second quarter truvada atripla sales expected continue decline first quarter beyond multiple generics expected enter market starting second quarter biktarvy trodelvy vemlidy cell therapy expected key growth drivers absorbing full year impact loss exclusivity truvada atripla united states veklury sales generated highly dynamic complex global environment continues evolve result veklury sales subject significant volatility uncertainty future product demand depend nature covid pandemic including duration pandemic infection rates hospitalizations availability alternative therapies vaccines developed acquisition immunomedics continue contribute revenue growth capital allocation priorities remain unchanged plan prioritize investment business rd pipeline maintain rigorous focus disciplined expense management ability deliver strategy objectives subject number uncertainties including limited effects covid pandemic remains unpredictable continuation uncertain global macroeconomic environment ability realize potential benefits acquisitions collaborations licensing arrangements ability initiate progress complete clinical trials within currently anticipated timeframes possibility unfavorable results new ongoing clinical trials additional pricing pressures payers competitors higher anticipated effects loss exclusivity truvada atripla slower anticipated growth biktarvy trodelvy vemlidy cell therapy products increase discounts chargebacks rebates due ongoing contracts future negotiations commercial government payers market share price erosion caused introduction generics loss exclusivity products inaccuracies hcv patient start estimates potential government actions could effect lowering prices largerthan anticipated shift payer mix highly discounted payer segment volatility foreign currency exchange rates results operations total revenues following table summarizes periodoverperiod changes revenues millions except percentages change change product sales hiv products hcv products veklury nm nm cell therapy products trodelvy nm nm products total product sales royalty contract revenues total revenues nm meaningful compared total product sales total product sales increased billion compared billion primarily due veklury sales higher product sales hiv products including continued patient uptake biktarvy growth descovy prep increase partially offset lower sales volume truvada ftctdfbased products primarily due loss exclusivity truvada atripla united states october lower hcv sales due lower patient starts due covid pandemic expected declines sales letairis ranexa generic entries first half hiv product sales hiv product sales increased billion compared billion primarily due continued patient uptake biktarvy growth descovy prep partially offset lower sales volume truvada ftctdfbased products driven loss exclusivity truvada atripla united states october lower average net selling price driven unfavorable payer mix primarily due higher public health service utilization hiv franchise including prep also unfavorably impacted covid pandemic hiv product sales included favorable net adjustments primarily due government rebates discounts descovy ftctafbased product sales increased major markets compared increase united states primarily due continued patient uptake biktarvy growth descovy prep partially offset lower sales volume genvoya increase europe international locations primarily due higher sales volume biktarvy partially offset lower sales volume genvoya truvada ftctdfbased product sales decreased united states europe compared decrease united states primarily due lower sales volume driven loss exclusivity truvada atripla october patients switching regimens containing ftctaf expect truvada sales continue decline beyond multiple generics expected enter market starting second quarter decrease european sales primarily due lower sales volume result broader availability generic versions truvada patients switching regimens containing ftctaf hcv product sales hcv product sales decreased billion compared billion primarily due lower sales volume driven lower patient starts united states europe attributable covid pandemic continuing decline total market patient starts unrelated pandemic well lower average net selling price reflecting higher sales return provisions discounts hcv product sales included favorable net adjustments primarily due government rebates discounts decrease hcv product sales united states europe compared primarily due lower patient starts including declines attributable decrease health care provider visits screenings due covid pandemic well lower average net selling price decrease europe also impacted favorable net adjustments primarily due government rebates discounts reoccur decrease hcv product sales international locations compared primarily due lower sales volume veklury veklury generated billion sales primarily united states europe reflecting higher hospitalization treatment rates due fourth quarter covid surge cell therapy product sales cell therapy product sales include yescarta tecartus increased million compared million primarily due continued uptake yescarta europe third quarter product launch tecartus united states trodelvy trodelvy generated million sales united states following acquisition immunomedics october product sales product sales include vemlidy viread letairis ranexa zydelig ambisome cayston jyseleca decreased billion compared billion primarily due expected declines sales letairis ranexa generic entries first half partially offset higher sales volume vemlidy international locations grosstonet deductions record product sales net estimated government rebates chargebacks cash discounts prompt payment distributor fees sales return provisions related costs deductions product sales generally referred grosstonet gtn deductions totaled billion gross product sales compared billion gross product sales billion billion gross product sales related government rebates chargebacks billion related cash discounts prompt payment distributor fees related costs million related sales return provisions product sales geographic area total product sales generated outside united states respectively faced exposure movements foreign currency exchange rates primarily euro used foreign currency exchange contracts hedge percentage foreign currency exposure foreign currency exchange net hedges unfavorable impact product sales million based comparison using foreign currency exchange rates product sales united states increased billion compared billion primarily due sales veklury continued patient uptake biktarvy growth descovy prep partially offset decreases sales truvada ftctdfbased products driven loss exclusivity truvada atripla united states october increase also partially offset lower sales volume letairis ranexa lower sales hcv products decrease sales hcv products primarily due lower patient starts average net selling price discussed product sales europe increased billion compared billion primarily due sales veklury continued patient uptake biktarvy yescarta increase partially offset lower patient starts average net selling price discussed product sales europe included favorable net adjustments primarily due government rebates discounts product sales international locations increased billion compared billion primarily due higher sales volumes biktarvy veklury vemlidy following table summarizes periodoverperiod changes product sales millions except percentages change change hiv products descovy ftctaf based products biktarvy us nm biktarvy europe nm biktarvy international nm nm nm descovy us descovy europe descovy international nm genvoya us genvoya europe genvoya international odefsey us odefsey europe odefsey international revenue share symtuza us nm revenue share symtuza europe nm revenue share symtuza international nm nm nm total descovy ftctaf based products us total descovy ftctaf based products europe total descovy ftctaf based products international nm truvada ftctdf based products atripla us atripla europe atripla international complera eviplera us complera eviplera europe complera eviplera international stribild us stribild europe stribild international truvada us truvada europe truvada international total truvada ftctdf based products us total truvada ftctdf based products europe total truvada ftctdf based products international hiv us hiv europe hiv international nm total hiv us total hiv europe total hiv international hcv products ledipasvir sofosbuvir us ledipasvir sofosbuvir europe ledipasvir sofosbuvir international sofosbuvir velpatasvir us sofosbuvir velpatasvir europe sofosbuvir velpatasvir international hcv us hcv europe hcv international total hcv us total hcv europe total hcv international veklury veklury us nm nm veklury europe nm nm veklury international nm nm nm nm cell therapy products yescarta us yescarta europe nm nm yescarta international nm nm tecartus us nm nm tecartus europe nm nm tecartus international nm nm nm nm total cell therapy us total cell therapy europe nm nm total cell therapy international nm nm trodelvy us nm nm products ambisome us ambisome europe ambisome international letairis us ranexa us vemlidy us vemlidy europe vemlidy international nm viread us viread europe viread international zydelig us zydelig europe zydelig international us europe international total us total europe total international total product sales us total product sales europe total product sales international nm meaningful represents revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland unlimited company includes emtriva tybost amounts consist sales harvoni authorized generic version harvoni sold separate subsidiary asegua therapeutics llc amounts consist sales epclusa authorized generic version epclusa sold separate subsidiary asegua therapeutics llc includes vosevi sovaldi includes cayston hepsera jyseleca costs expenses following table summarizes periodoverperiod changes costs expenses millions except percentages change change cost goods sold product gross margin bps bps research development rd expenses acquired iprd expenses nm selling general administrative sga expenses nm meaningful cost goods sold product gross margin cost goods sold decreased million compared primarily due inventory writedown charges million million related slow moving excess raw material work process inventory primarily due lower longterm demand hcv products decrease cost goods sold partially offset higher manufacturing rampup expenses related veklury treatment covid acquisitionrelated expenses amortization finitelived intangible assets inventory stepup charges well accelerated stockbased compensation expenses related acquisition immunomedics addition royalty expenses decreased million compared primarily due lower sales products containing elvitegravir letairis atripla product gross margin increased compared primarily due factors described research development expenses rd expenses consist primarily clinical studies performed contract research organizations materials supplies payments collaborative arrangements including milestone payments licenses fees expense reimbursements collaboration partners personnel costs including salaries benefits stockbased compensation expense overhead allocations consisting various support infrastructure costs track total rd expenses product candidate therapeutic area development phase however manage rd expenses identifying rd activities anticipate performed given period prioritizing efforts based scientific data probability technical regulatory successful development market potential available human capital resources considerations continually review rd projects based unmet medical need necessary reallocate resources among internal rd portfolio external opportunities believe best support longterm growth business following table provides breakout rd expenses major cost type millions except percentages change change clinical studies outside services personnel infrastructure expenses stockbased compensation expenses total rd expenses increased billion compared primarily due higher clinical trial expenses related investigation remdesivir treatment covid including material costs fourth quarter charge million million connection agreement amend existing arrangement galapagos commercialization development jyseleca accelerated stockbased compensation expenses million related acquisitions immunomedics forty seven higher investments oncology programs including magrolimab investigational anticd monoclonal antibody lesser extent trodelvy accruals milestone payments million pionyr immunotherapeutics inc pionyr increase partially offset lower clinical trial expenses completion certain inflammation programs lower costs result pause postponement certain clinical trials due covid pandemic acquired inprocess research development expenses acquired iprd expenses reflect iprd impairments well initial costs externally developed iprd projects acquired directly transaction business combination alternative future use including upfront payments related various collaborations initial costs rights iprd projects beginning second quarter acquired iprd expenses reported separately research development expenses consolidated statements income iprd assets capitalized tested impairment fourth quarter year earlier impairment indicators exist iprd impairment charges recorded acquired iprd expenses billion primarily related acquisition forty seven well collaborations investments entered year arcus biosciences inc pionyr tango therapeutics inc tizona therapeutics inc jounce therapeutics inc acquired iprd expenses billion included billion upfront charges related global research development collaboration agreement galapagos million impairment charge assets obtained kite acquisition selling general administrative expenses sga expenses relate sales marketing finance human resources legal administrative activities including information technology investments expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include branded prescription drug bpd fee united states along pharmaceutical manufacturers branded drug products required pay portion bpd fee estimated based select government sales prior year percentage total industry government sales truedup upon receipt invoices internal revenue service sga expenses increased million compared primarily due accelerated stockbased compensation expenses million related acquisitions immunomedics forty seven million charge related previously disclosed legal settlement increased corporate grants costs associated commercialization efforts veklury lesser extent trodelvy higher marketing expenses related biktarvy donations remdesivir increases partially offset lower travel spend due covid pandemic bpd fee expenses million million million respectively bpd fee expenses taxdeductible income expense net interest expense following table summarizes periodoverperiod changes income expense net interest expense millions except percentages change change income expense net nm nm interest expense nm meaningful unrealized losses primarily relating investments galapagos unfavorably impacted income expense net compared unrealized gains income taxes following table summarizes periodoverperiod changes income tax expense benefit millions except percentages income income taxes income tax expense benefit effective tax rate effective tax rate increased compared primarily due billion acquired iprd charge recorded connection acquisition forty seven million certain acquired iprd charges billion unfavorable changes fair value equity investments galapagos nondeductible tax purposes effective tax rate included billion discrete tax benefit related intraentity intangible asset transfers different tax jurisdictions liquidity capital resources following table summarizes cash cash equivalents marketable debt securities working capital december millions cash cash equivalents marketable debt securities working capital cash cash equivalents marketable debt securities cash cash equivalents marketable debt securities december decreased billion compared december generated billion operating cash flow utilized billion acquisitions including iprd net cash acquired issued senior unsecured notes aggregate principal amount billion net issuance costs borrowed aggregate principal amount billion threeyear term loan facility repaid billion principal amount debt paid cash dividends billion utilized billion repurchases common stock january repaid billion senior unsecured notes prior april maturity may choose repay certain longterm debt obligations prior maturity dates based assessment current longterm liquidity capital requirements acquisition myr gmbh expected close first quarter per agreement make consideration payment approximately billion cash approximately billion upon closing working capital working capital current assets less current liabilities decreased billion compared december primarily due utilization significant cash cash equivalents marketable debt securities acquisitions immunomedics forty seven noted reclassifications senior unsecured notes longterm debt net decrease partially offset increased accounts receivables due veklury sales reclassification portion galapagos equity investments longterm assets accounts receivable increased billion compared december primarily reflecting increased sales driven veklury due covid surge fourth quarter accrued liabilities increased billion compared december primarily due reclassification longterm income taxes payable certain tax payments expected made within year cash flows following table summarizes cash flow activities millions net cash provided used operating activities investing activities financing activities operating activities cash provided operating activities represents cash receipts disbursements related activities investing financing activities operating cash flow derived adjusting net income noncash items changes operating assets liabilities cash provided operating activities decreased million billion compared decrease primarily result changes working capital reflecting increases accounts receivable fourth quarter veklury sales certain tax payments made taxing authorities investing activities cash used provided investing activities primarily consists purchases sales maturities marketable debt securities capital expenditures acquisitions including iprd net cash acquired purchases equity securities investments cash used investing activities billion compared billion change cash used provided investing activities due billion payments made primarily related acquisitions immunomedics forty seven compared billion payments made primarily related collaboration equity investments galapagos financing activities change cash provided used financing activities compared primarily due billion proceeds september senior unsecured notes offering net issuance costs million borrowed threeyear term loan facility net issuance costs october connection acquisition immunomedics debt credit facilities summary borrowings various financing arrangements included note debt credit facilities notes consolidated financial statements included item annual report may choose repay certain longterm debt obligations prior maturity dates based assessment current longterm liquidity capital requirements senior unsecured notes offering september connection acquisition immunomedics issued senior unsecured notes consisting million principal amount floating rate notes due september million principal amount floating rate notes due september ii billion principal amount senior notes due september million principal amount senior notes due october billion principal amount senior notes due october billion principal amount senior notes due october billion principal amount senior notes due october senior unsecured notes repayments repaid maturity billion billion principal amount senior unsecured notes respectively january repaid billion senior unsecured notes prior april maturity term loan facility october connection acquisition immunomedics borrowed aggregate principal amount billion threeyear term loan facility term loan facility liability related future royalties connection acquisition immunomedics assumed liability related funding arrangement originally entered immunomedics rpi finance trust rpi liability related future royalties primarily included longterm debt net consolidated balance sheets see note acquisitions notes consolidated financial statements included item annual report additional information credit facility june terminated billion revolving credit facility maturing may revolving credit facility entered new billion revolving credit facility maturing june revolving credit facility terms substantially similar revolving credit facility revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions december amounts outstanding revolving credit facilities required comply certain covenants notes indentures december violation covenants capital return program details stock repurchase programs dividends included note stockholders equity notes consolidated financial statements included item annual report stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions started repurchases program april purchased million million shares common stock program billion billion respectively first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions december remaining authorized repurchase amount programs billion dividends declared paid quarterly cash dividends aggregate amount billion per share common stock billion per share common stock respectively february announced board directors declared quarterly cash dividend increase per share common stock payment date march stockholders record close business march future dividends subject declaration board directors capital resources believe existing capital resources supplemented cash flows generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products debt service requirements establishment additional collaborative relationships companies costs associated defense settlement adverse results government investigations litigation may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements included item annual report prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition recognize revenue product sales control product transfers generally upon shipment delivery customer certain cases upon corresponding sales customer third party revenues recognized net estimated government rebates chargebacks cash discounts prompt payment distributor fees sales return provisions related deductions deductions product sales referred gtn deductions estimated recorded period related product sales occur variable consideration included net sales price extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated variable consideration subsequently resolved government rebates chargebacks represent majority gtn deductions subject complex estimation process requires significant judgment management part due lag date product sales date related rebates chargeback claims settled government rebates chargebacks include amounts payable payers healthcare providers various programs may vary product payer individual payer plans qualified programs purchase products wholesalers distributors lower contractual price wholesalers distributors charge back us difference acquisition cost lower contractual price rebates chargebacks estimated primarily based product sales expected payer mix discount rates require significant estimates judgment additionally developing estimates government rebates chargebacks consider following factors historical estimated payer mix statutory discount requirements contractual terms historical claims experience processing time lags estimated patient population known market events trends market research channel inventory data obtained major us wholesalers pertinent internal external information assess update estimates every quarter reflect actual claims current information actual government rebates chargebacks claimed prior periods varied estimates less amounts deducted product sales years ended december believe methodology use estimate government rebates chargebacks reasonable appropriate given current facts circumstances however actual results may differ significantly estimates government chargebacks payable direct customers classified reductions accounts receivable consolidated balance sheets totaled million million december respectively see note financial information notes consolidated financial statements included item annual report additional information government rebates payable third party payers healthcare providers generally recorded accrued government rebates consolidated balance sheets totaled billion december allowance sales returns generally recorded accrued liabilities consolidated balance sheets totaled million million december respectively increase allowance sales returns reflects estimated veklury sales returns increase hcv hiv sales return provisions following table summarizes consolidated activities ending balances government rebates chargebacks accounts balance decreaseincrease balance end millions beginning year product sales payments year year ended december activity related sales activity related sales prior total year ended december activity related sales activity related sales prior total acquisitions valuation intangibles make certain judgments determine whether transactions accounted acquisitions assets business combinations determined substantially fair value gross assets acquired transaction concentrated single asset group similar assets transaction treated acquisition assets evaluate inputs processes outputs associated acquired set activities assets transaction include input substantive process together significantly contribute ability create outputs transaction treated acquisition business account business combinations using acquisition method accounting requires assets acquired liabilities assumed generally recorded fair values acquisition date excess consideration fair value net assets acquired recorded goodwill estimating fair value requires us make significant judgments assumptions perform impairment testing goodwill annually frequently events changes circumstances indicate likely asset impaired transactions accounted acquisitions assets goodwill recorded contingent consideration payments upon achievement various developmental regulatory commercial milestones generally recognized acquisition date asset acquisition upfront payments allocated iprd projects acquisition date expensed unless alternative future use addition product development milestones expensed upon achievement valuation intangible assets acquired expect continue acquire intangible assets asset acquisition business combination consolidation variable interest entities identifiable intangible assets measured respective fair values acquisition date intangible assets acquired business combinations subject potential adjustments within measurement period one year acquisition date fair values intangible assets generally determined using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar profile represents rate market participants would use value intangible assets discounted cash flow models used valuing intangible assets require use significant estimates assumptions including limited identification product candidates sufficient substance requiring separate recognition estimates projected future cash flows including revenues operating profits related products product candidates probability technical regulatory success unapproved product candidates considering stages development time resources needed complete development approval product candidates appropriate discount rate life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets believe fair values used record intangible assets acquired based upon reasonable estimates assumptions given facts circumstances related valuation dates impairment amortization intangible assets intangible assets related iprd projects acquired business combination capitalized indefinitelived intangible assets completion abandonment associated rd efforts period assets considered indefinitelived amortized development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived amortized based respective estimated useful lives point time primarily straightline basis indefinitelived intangible assets tested impairment annually frequently events changes circumstances indicate likely assets impaired estimates fair value result complex series judgments future events uncertainties make assumptions point time acquisition date subsequent impairment assessment date changes estimates assumptions including timing product launch pricing reductions failure obtain anticipated regulatory approval deterioration us global financial markets unanticipated events circumstances may decrease projected cash flows increase discount rate could potentially result impairment charge eventual realized value acquired iprd project may vary fair value date acquisition carrying value intangible asset exceeds estimated fair value impairment charge recorded write intangible asset estimated fair value example recognized million impairment charge related iprd projects primarily treatment indolent nonhodgkin lymphoma due changes estimated market opportunities high rate failure inherent discovery development new products example concluded kite program acquired connection acquisition kite justify efforts based totality clinical data gathered discontinued program result carrying value iprd relating kite program written zero recorded impairment charge million intangible assets also periodically reviewed changes facts circumstances resulting reduction estimated useful life asset requiring acceleration amortization see note goodwill intangible assets notes consolidated financial statements included item annual report additional information impairment charges related indefinitelived iprd intangible assets legal contingencies party various legal actions significant described note commitments contingencies legal proceedings notes consolidated financial statements included item annual report possible determine outcome matters recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine loss reasonably possible loss range loss estimated disclose possible loss significant judgment required determination probability determination whether exposure reasonably estimable inherent uncertainty unpredictability related matters accruals based believe best information available time assessment including legal facts circumstances case status proceedings applicable law views legal counsel upon final resolution matters possible may loss excess amount recorded amounts could material adverse effect results operations cash flows financial position periodically reassess matters additional information becomes available adjust estimates assumptions facts circumstances indicate need changes material accruals consolidated balance sheets matters december income taxes estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering made changes existing tax laws example united states enacted significant tax reform certain provisions new law continue significantly affect us predict form timing potential legislative changes could material adverse impact results operations addition significant judgment required determining worldwide provision income taxes record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return adverse resolution one uncertain tax positions period could material impact results operations period see note income taxes notes consolidated financial statements included item annual report additional information balance sheet arrangements balance sheet arrangements defined item aii regulation sk contractual obligations contractual obligations represent future cash commitments related significant enforceable legally binding obligations certain purchase obligations likely continue regardless fact may cancelable expected timing payment amounts presented estimated based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts following table summarizes aggregate maturities contractual obligations december payments due period millions total thereafter debt operating lease obligations purchase obligations transition tax payable total debt includes principal future interest payments senior unsecured notes term loan facility interest payments fixed rate senior unsecured notes incurred calculated based terms related notes debt also includes liability related future royalty obligations assumed acquisition immunomedics see note acquisitions note debt credit facilities notes consolidated financial statements included item annual report additional information see note leases notes consolidated financial statements included item annual report additional information amounts primarily relate active pharmaceutical ingredients api minimum purchase commitments certain inventoryrelated items rd commitments capital commitments significant rd commitments related clinical studies performed contract research organizations cros excluded table material cro contracts cancelable us connection tax reform recorded federal income tax payable transition tax mandatory deemed repatriation foreign earnings payable eightyear period amounts included table represent remaining federal income tax payable december december longterm income taxes payable includes unrecognized tax benefits interest penalties totaling billion due high degree uncertainty timing future cash settlement events could extinguish unrecognized tax benefits unable estimate period cash settlement therefore excluded unrecognized tax benefits table committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally contingent upon certain future events including achievement certain developmental regulatory commercial milestones achievement events neither probable reasonably estimable potential payments recorded consolidated balance sheets included table consideration payment approximately billion cash approximately billion acquisition myr gmbh expected close end first quarter excluded table see note acquisitions notes consolidated financial statements included item annual report additional information recent accounting pronouncements information required item included note organization summary significant accounting policies notes consolidated financial statements included item annual report item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit risks market price reduce certain risks enter various types foreign currency interest rate derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program foreign currency exchange risk operations countries worldwide result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business approximately product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales may enter foreign currency exchange forward option contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million million respectively date realized would negatively affect earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate risk portfolio availableforsale debt securities senior unsecured notes create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december expected maturity total fair millions except percentages thereafter total value assets availableforsale debt securities average interest rate liabilities senior unsecured fixed rate notes including current portion average interest rate senior unsecured floating rate notes term loan including current portion average interest rate amounts represent principal balances addition senior unsecured fixed rate notes billion fiveyear revolving credit facility matures june amounts outstanding fiveyear revolving credit facility december see note debt credit facilities notes consolidated financial statements included item annual report additional information market price risk hold shares common stock certain publicly traded biotechnology companies primarily connection license collaboration agreements equity securities measured fair value changes fair value recognized earnings fair value equity securities approximately billion billion december respectively changes fair value equity securities impacted volatility stock market changes general economic conditions among factors hypothetical increase decrease stock prices equity securities would increase decrease fair value december approximately million million respectively item financial statements supplementary data gilead sciences inc index consolidated financial statements supplementary data years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm stockholders board directors gilead sciences inc opinion financial statements audited accompanying consolidated balance sheets gilead sciences inc company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes collectively referred consolidated financial statements opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility companys management responsibility express opinion companys financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matters critical audit matters communicated matters arising current period audit financial statements communicated required communicated audit committee relate accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate government commercial rebates description matter fully described note company estimates reductions revenues amounts payable payers healthcare providers united states various government commercial rebate programs period related sales occur rebates may vary product payer individual payer plans may known point sale estimated reductions revenue based product sales historical expected payer mix discount rates various estimated actual data adjusted current period expectations auditing companys estimated reductions revenue rebates complex involved significant judgment particularly assessing reasonableness estimated payer mix applied sales period estimate relies heavily historical data adjusted changes payer mix expectations time addressed evaluated tested design operating effectiveness companys internal controls managements estimation matter audit review reductions revenue rebate programs including controls assess payer mix assumption also tested completeness accuracy data utilized controls accuracy calculations supporting managements estimates test managements estimation methodology determining payer mix audit procedures included among others evaluating evidence contrary estimated amounts performing sensitivity analysis rates used estimates performing comparison actual payments related amounts accrued current prior years valuation inprocess research development intangible assets description matter december companys inprocess research development iprd intangible assets acquisitions prior billion discussed note intangible assets indefinite useful lives related purchased iprd projects measured respective fair values acquisition date considered indefinitelived completion abandonment associated rd efforts company tests indefinitelived intangible assets impairment annual basis annual tests become aware events changes would indicate fair values assets carrying amounts auditing impairment test complex due significant judgment required estimating fair values iprd intangible assets particular fair value estimates required use valuation methodologies sensitive significant assumptions eg discount rate projected research development costs probability technical success addressable patient population projected market share product profitability affected expected future market economic conditions addressed evaluated tested design operating effectiveness companys internal controls determination matter audit estimated fair value iprd intangible assets example tested controls management 's review valuation methodologies significant assumptions used develop fair value estimates also tested management 's controls validate data used fair value estimates complete accurate test estimated fair value companys iprd intangible assets audit procedures among others included evaluating companys use appropriate valuation methodologies assistance valuation specialist performing sensitivity analyses determine assumptions greatest impact overall determination value testing completeness accuracy underlying data audit procedures significant assumptions included comparing assumptions current industry market economic trends historical results companys business guideline companies within industry relevant factors example evaluate probability technical success considered phase development iprd projects company 's history obtaining regulatory approval valuation intangible assets acquired business combination description matter described note october company completed acquisition immunomedics inc immunomedics billion cash consideration transaction accounted business combination using acquisition method accounting acquisition date fair values acquired finitelived intangible assets comprised commercial product rights indefinitelived intangible assets comprised iprd intangible assets estimated billion billion respectively using probabilityweighted income approach discounts expected future cash flows present value auditing acquisition date fair values intangible assets acquired immunomedics complex due significant judgment required estimating fair values asset particular fair value estimates required use valuation methodologies sensitive significant assumptions eg discount rate projected research development costs probability technical success addressable patient population treatment duration projected market share product profitability affected expected future market economic conditions addressed evaluated tested design operating effectiveness companys internal controls determination matter audit estimated fair value intangible assets example tested controls management 's review valuation methodologies significant assumptions used develop fair value estimates intangible assets also tested management 's controls validate data used fair value estimates complete accurate test estimated fair value company 's intangible assets acquired immunomedics audit procedures among others included evaluating company 's use appropriate valuation methodologies assistance valuation specialist performing sensitivity analyses determine assumptions greatest impact overall determination value testing completeness accuracy underlying data used develop assumptions audit procedures significant assumptions included comparing significant assumptions current industry market economic trends historical results company 's business guideline companies within industry relevant factors example evaluated probability technical success considering phase development clinical projects company 's history obtaining regulatory approval addition evaluated expected addressable patient populations comparing companys estimates external industry forecasts ernst young llp served companys auditor since san jose california february gilead sciences inc consolidated balance sheets december millions except per share amounts assets current assets cash cash equivalents shortterm marketable securities accounts receivable net inventories prepaid current assets total current assets property plant equipment net longterm marketable securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued liabilities current portion longterm debt obligations net total current liabilities longterm debt net longterm income taxes payable longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share authorized shares issued outstanding respectively additional paidin capital accumulated comprehensive income retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes gilead sciences inc consolidated statements income year ended december millions except per share amounts revenues product sales royalty contract revenues total revenues costs expenses cost goods sold research development expenses acquired inprocess research development expenses selling general administrative expenses total costs expenses income operations interest expense income expense net income income taxes income tax expense benefit net income net loss income attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculation basic net income per share attributable gilead common stockholders diluted shares used per share calculation diluted see accompanying notes gilead sciences inc consolidated statements comprehensive income year ended december millions net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale debt securities net unrealized gain net tax reclassifications net income net tax net change cash flow hedges net unrealized gain loss net tax reclassification net income net tax net change comprehensive income loss comprehensive income loss comprehensive income loss attributable noncontrolling interest comprehensive income loss attributable gilead see accompanying notes gilead sciences inc consolidated statements stockholders equity millions except per share amounts gilead stockholders equity accumulated common stock additional total paidin comprehensive retained noncontrolling stockholders millions except per share amounts shares amount capital income loss earnings interest equity balance december cumulative effect adoption new accounting standards change noncontrolling interest net income comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december cumulative effect adoption new accounting standards net income loss comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december cumulative effect adoption new accounting standard note change noncontrolling interest note net income loss comprehensive income loss net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december see accompanying notes gilead sciences inc consolidated statements cash flows year ended december millions operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense deferred income taxes net gains losses equity securities acquired inprocess research development expenses inprocess research development impairment writedowns slow moving excess raw material work process inventory changes operating assets liabilities accounts receivable net inventories prepaid expenses accounts payable income taxes payable accrued liabilities net cash provided operating activities investing activities purchases marketable debt securities proceeds sales marketable debt securities proceeds maturities marketable debt securities acquisitions including inprocess research development net cash acquired purchases equity securities capital expenditures net cash used provided investing activities financing activities proceeds debt financing net issuance costs proceeds issuances common stock repurchases common stock repayments debt obligations payment dividends net cash provided used financing activities effect exchange rate changes cash cash equivalents net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include hiv viral hepatitis cancer seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategic collaborations portfolio marketed products includes ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepsera jyseleca letairis odefsey ranexa sovaldi stribild tecartustm trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status jyseleca varies worldwide jyseleca approved united states also sell distribute authorized generic versions epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain products corporate partners collaborative agreements basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries certain variable interest entities primary beneficiary intercompany transactions eliminated consolidated entities exposed less economics record net income loss attributable noncontrolling interests consolidated statements income equal percentage economic ownership interest retained entities respective noncontrolling parties assess whether primary beneficiary variable interest entity vie inception arrangement reporting date assessment based power direct activities vie significantly impact vies economic performance obligation absorb losses right receive benefits vie could potentially significant vie segment information one operating segment primarily focuses discovery development commercialization innovative medicines areas unmet medical need chief executive officer ceo chief operating decisionmaker manages allocates resources operations company entitywide basis managing allocating resources entitywide basis enables ceo assess overall level resources available best deploy resources across functions research development rd projects based unmet medical need necessary reallocate resources among internal rd portfolio external opportunities best support longterm growth business see note revenues summary disaggregated revenues product geographic region significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate significant accounting policies estimates base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources estimates assessed period updated reflect current information economic considerations related impact recent coronavirus disease covid could significant accounting estimates actual results may differ significantly estimates reclassification beginning acquired inprocess research development iprd expenses reported separately research development expenses consolidated statements income acquired iprd expenses consolidated statements income reflect iprd impairments well initial costs externally developed iprd projects acquired directly transaction business combination alternative future use including upfront payments related various collaborations initial costs rights iprd projects consolidated statements income years ended december conformed separately present acquired iprd expenses consolidated statement cash flows year ended december conformed separately present acquired iprd expenses exclusive iprd impairments comparative amounts consolidated statement cash flows year ended december material change income operations operating cash flow result reclassifications revenue recognition product sales recognize revenue product sales control product transfers generally upon shipment delivery customer certain cases upon corresponding sales customer third party revenues recognized net estimated government rebates chargebacks cash discounts prompt payment distributor fees sales return provisions related deductions deductions product sales referred grossto net deductions estimated recorded period related product sales occur payment terms customers generally range days however payment terms differ jurisdiction customer instances type product variable consideration included net sales price extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated variable consideration subsequently resolved expect contract inception period transfer control corresponding payment customer one year less adjust amount consideration effects significant financing component gross net deductions rebates chargebacks government rebates chargebacks include amounts payable payers healthcare providers various programs may vary product payer individual payer plans rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans qualified programs purchase products wholesalers distributors lower contractual price wholesalers distributors charge back us difference acquisition cost lower contractual price rebates chargebacks estimated primarily based product sales expected payer mix discount rates require significant estimates judgment additionally developing estimates consider historical estimated payer mix statutory discount requirements contractual terms historical claims experience processing time lags estimated patient population known market events trends market research channel inventory data obtained major us wholesalers pertinent internal external information assess update estimates every quarter reflect actual claims current information government chargebacks payable direct customers generally classified reductions accounts receivable consolidated balance sheets government rebates payable third party payers healthcare providers recorded accrued government rebates consolidated balance sheets cash discounts estimate cash discounts based contractual terms historical customer payment patterns expectations regarding future customer payment patterns distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales allowance sales returns allowances made estimated sales returns customers recorded period related revenue recognized typically permit returns product damaged defective otherwise used customer united states typically permit returns six months prior one year product expiration date outside united states returns allowed certain countries limited basis estimates sales returns based primarily analysis historical product return patterns industry information reporting return rates similar products contractual agreement terms also take consideration known expected changes marketplace specific product shipping handling shipping handling activities considered fulfillment activities considered separate performance obligation royalty contract revenues royalty revenue recognized period obligation satisfied corresponding sales corporate partners occur research development expenses rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies payments collaborative arrangements including milestone payments license option fees well expense reimbursements collaboration partners overhead allocations consisting various support infrastructure costs upfront milestone payments made thirdparty collaborators expensed incurred point regulatory approval milestone payments made upon regulatory approval capitalized amortized remaining useful life related product time time enter development collaboration agreements share expenses collaborative partner record payments received collaborative partners share development costs reduction research development expense charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination payments make research development services prior services rendered recorded prepaid assets consolidated balance sheets expensed services provided selling general administrative expenses selling general administrative sga expenses relate sales marketing finance human resources legal administrative activities sga expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include branded prescription drug bpd fee united states along pharmaceutical manufacturers branded drug products required pay portion bpd fee estimated based select government sales prior year percentage total industry government sales expense costs advertising including promotional expenses incurred advertising expenses million million million years ended december respectively cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents marketable nonmarketable securities marketable debt securities determine appropriate classification marketable debt securities time purchase reevaluate designation balance sheet date marketable debt securities considered availableforsale carried estimated fair values reported cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale debt securities excluded net income reported accumulated comprehensive income loss aoci separate component stockholders equity income expense net includes interest amortization purchase premiums discounts realized gains losses sales securities expected credit losses cost securities sold based specific identification method regularly review investments declines fair value amortized cost basis determine whether impairment due creditrelated factors noncreditrelated factors review includes creditworthiness security issuers number securities unrealized loss position severity unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine portion unrealized loss due expected credit loss recognize loss amount income expense net corresponding allowance carrying value security hold portion unrealized loss related factors credit losses recognized aoci marketable nonmarketable equity securities investments equity securities equity method investments recorded fair market value fair value readily determinable unrealized gains losses included income expense net consolidated statements income investments entities significant influence meet requirements consolidation elected fair value option use equity method accounting share underlying income loss entities reported income expense net consolidated statements income elected fair value option account equity investment galapagos nv galapagos significant influence believe fair value option best reflects underlying economics investment see note collaborations arrangements additional information equity securities without readily determinable fair values recorded using measurement alternative cost less impairment adjusted observable price changes orderly transactions identical similar investments issuer certain investments equity securities nonpublic companies accounted using equity method based ownership percentage factors indicate significant influence investee see note collaborations arrangements additional information investments equity securities recorded prepaid current assets longterm assets consolidated balance sheets regularly review securities indicators impairment concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales trade accounts receivable recorded net allowances wholesaler chargebacks related government programs cash discounts prompt payment credit losses estimates allowance credit losses consider number factors including existing contractual payment terms individual customer circumstances historical payment patterns customers review local economic environment potential impact expected future customer payment patterns government funding reimbursement practices majority trade accounts receivable arises product sales united states europe japan material writeoffs charged allowance year ended december certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials inventories inventories recorded lower cost net realizable value cost determined firstin firstout basis periodically review inventories identify obsolete slow moving excess otherwise unsaleable items obsolete slow moving excess unsaleable items observed alternate uses inventory record writedown net realizable value charge cost goods sold consolidated statements income determination net realizable value requires judgment including consideration many factors estimates future product demand product net selling prices current future market conditions potential product obsolescence among others future commercialization considered probable future economic benefit expected realized based managements judgment capitalize prelaunch inventory costs prior regulatory approval number factors considered including current status regulatory approval process potential impediments approval process safety efficacy anticipated rd initiatives could impact indication compound used viability commercialization marketplace trends property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method repairs maintenance costs expensed incurred estimated useful lives years generally follows description estimated useful life buildings improvements shorter years useful life laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term leases january adopted accounting standards update topic leases requires lessees recognize rightofuse assets lease liabilities operating leases lease term greater one year adopted topic using modified retrospective method results reporting periods beginning january presented topic prior period amounts adjusted continue reported accordance historical accounting topic leases determine arrangement contains lease inception rightofuse assets lease liabilities recognized commencement date based present value lease payments lease term noncancelable period stated contract adjusted options extend terminate reasonably certain exercise option rightofuse assets adjusted prepaid lease payments lease incentives initial direct costs incurred operating lease expense minimum lease payments recognized straightline basis lease term account lease nonlease components lease agreements single lease component determining lease assets liabilities addition recognize rightofuse assets liabilities leases lease terms one year less operating leases provide implicit interest rate generally utilize collateralized incremental borrowing rate applied portfolio approach relevant based information available commencement date determine lease liability acquisitions account business combinations using acquisition method accounting generally requires assets acquired including iprd projects liabilities assumed recorded fair values acquisition date consolidated balance sheets excess consideration fair value net assets acquired recorded goodwill determination estimated fair value requires us make significant estimates assumptions result may record adjustments fair values assets acquired liabilities assumed within measurement period one year acquisition date corresponding offset goodwill transaction costs associated business combinations expensed incurred determine net assets acquired meet definition business combination acquisition method accounting transaction accounted acquisition assets therefore goodwill recorded contingent consideration payments upon achievement various developmental regulatory commercial milestones generally recognized acquisition date asset acquisition upfront payments allocated iprd projects acquisition date subsequent milestone payments charged expense consolidated statements income unless alternative future use goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets measured respective fair values acquisition date may subject adjustment within measurement period may one year acquisition date intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts amortize goodwill intangible assets indefinite useful lives goodwill indefinitelived intangible assets tested impairment annually frequently events changes circumstances indicate likely assets impaired development successfully completed generally occurs regulatory approval obtained associated assets deemed finitelived amortized respective estimated useful lives beginning point time intangible assets finite useful lives amortized estimated useful lives primarily straightline basis reviewed impairment facts circumstances indicate carrying value assets may recoverable impairment longlived assets longlived assets including property plant equipment finitelived intangible assets reviewed impairment whenever facts circumstances either internally externally may indicate carrying value asset may recoverable indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset carrying amount asset asset group asset asset group determined impaired excess carrying value asset asset group estimated fair value recognized impairment loss valuation contingent consideration resulting business combination connection certain acquisitions may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events record contingent consideration resulting business combination fair value acquisition date quarter thereafter revalue obligations record increases decreases fair value rd expense within consolidated statement income time related product candidate receives marketing approval increases decreases fair value contingent consideration liabilities result updates assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions acquisition date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates foreign currency translation transaction gains losses hedging contracts nonus entity operations recorded functional currency entity results operations nonus dollar functional currency entities translated us dollars using average currency rates assets liabilities translated using currency rates period end foreign currency translation adjustments recorded component aoci within stockholders equity foreign currency transaction gains losses recorded income expense net consolidated statements income net foreign currency transaction gains losses material years ended december hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrealized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes fair value financial instruments apply fair value accounting financial assets liabilities nonfinancial assets liabilities recognized disclosed fair value financial statements recurring basis define fair value price would received selling asset paid transfer liability orderly transaction market participants measurement date determining fair value measurements assets liabilities required recorded fair value consider principal advantageous market would transact marketbased risk measurements assumptions market participants would use pricing asset liability risks inherent valuation techniques transfer restrictions credit risks derivative financial instruments recognize derivative instruments either assets liabilities fair value consolidated balance sheets changes fair value derivatives designated part hedge transaction recorded period current earnings aoci changes fair value derivatives part hedge transaction recorded period current earnings assess inception ongoing basis whether derivatives used hedging transactions effective offsetting changes cash flows fair values hedged items determine forecasted transaction probable occurring discontinue hedge accounting affected portion hedge instrument related unrealized gain loss contract recognized income expense net consolidated statements income income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations applicable tax laws regulations record liabilities related unrecognized tax benefits accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return adverse resolution one uncertain tax positions period could material impact results operations period elected account tax global intangible lowtaxed income gilti enacted part tax cuts jobs act tax reform component tax expense period tax incurred period cost method significant accounting policies significant accounting policies described remaining appropriate notes consolidated financial statements recently adopted accounting pronouncements june financial accounting standards board fasb issued accounting standards update asu financial instrumentscredit losses measurement credit losses financial instruments since modified standard several asus collectively topic topic requires measurement recognition expected credit losses financial assets january adopted standard using modified retrospective approach adoption material impact consolidated financial statements connection adoption topic made accounting policy election measure allowance credit losses accrued interest receivable november fasb issued accounting standards update collaborative arrangements topic clarifying interaction topic topic asu asu clarifies certain transactions participants collaborative arrangement accounted topic revenue contracts customers counterparty customer addition update precludes entity presenting consideration transaction collaborative arrangement customer revenue counterparty customer transaction january adopted standard applied retrospectively january initially adopted topic adoption impact consolidated financial statements revenues disaggregation revenues revenues follows year ended december year ended december year ended december millions us europe international total us europe international total us europe international total product sales hiv products atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza total hiv product sales hepatitis c virus hcv products ledipasvirsofosbuvir sofosbuvirvelpatasvir hcv total hcv product sales veklury cell therapy products yescarta tecartus total cell therapy product sales trodelvy products ambisome letairis ranexa vemlidy viread zydelig total product sales total product sales royalty contract revenues total revenues includes emtriva tybost represents revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland unlimited company amounts consist sales harvoni authorized generic version harvoni sold separate subsidiary asegua therapeutics llc amounts consist sales epclusa authorized generic version epclusa sold separate subsidiary asegua therapeutics llc includes vosevi sovaldi includes cayston hepsera jyseleca revenues major customers following table summarizes revenues customers individually accounted total revenues year ended december percentage total revenues amerisourcebergen corporation cardinal health inc mckesson corporation revenues recognized performance obligations satisfied prior periods revenues recognized performance obligations satisfied prior years related royalties licenses intellectual property million million years ended december respectively variable consideration included net sales price extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated variable consideration subsequently resolved estimates assessed period updated reflect current information changes estimates variable consideration related sales made prior years resulted million increase million increase revenues years ended december respectively contract balances contract assets consist unbilled amounts primarily arrangements licensing intellectual property predominant performance obligation totaled million million december respectively contract liabilities million million december respectively revenue recognized included contract liability balance beginning respective years material revenue expected recognized future contract liabilities related performance obligations satisfied expected material one year fair value measurements determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability marketable securities review trading activity pricing measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation financial instruments consist primarily cash cash equivalents marketable debt securities accounts receivable foreign currency exchange contracts equity securities accounts payable shortterm longterm debt cash cash equivalents marketable debt securities certain equity securities foreign currency exchange contracts reported respective fair values consolidated balance sheets equity securities without readily determinable fair values recorded using measurement alternative cost less impairment adjusted observable price changes orderly transactions identical similar investments issuer shortterm longterm debt reported amortized costs consolidated balance sheets remaining financial instruments reported consolidated balance sheets amounts approximate current fair values following table summarizes types assets liabilities measured fair value recurring basis level within fair value hierarchy december december millions level level level total level level level total assets availableforsale debt securities us treasury securities certificates deposit us government agencies securities nonus government securities corporate debt securities residential mortgage assetbacked securities equity securities equity investment galapagos money market funds publicly traded equity securities deferred compensation plan foreign currency derivative contracts total liabilities deferred compensation plan foreign currency derivative contracts total equity investments measured fair value excluded table limited partnerships equity method investments million million december respectively equity investments without readily determinable fair values million million december respectively amounts included longterm assets consolidated balance sheets changes fair value equity securities resulted net unrealized losses billion net unrealized gains billion years ended december respectively included income expense net consolidated statements income following table summarizes classification equity securities consolidated balance sheets millions december december cash cash equivalents prepaid current assets longterm assets total availableforsale debt securities classified cash equivalents shortterm marketable securities longterm marketable securities consolidated balance sheets see note availableforsale debt securities additional information see note collaborations arrangements additional information equity investment galapagos level inputs estimate fair values level instruments taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including incomebased marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs substantially foreign currency derivative contracts maturities within month time horizon counterparties minimum credit rating equivalent sp global ratings moodys investors service inc fitch ratings inc estimate fair values contracts taking consideration valuations obtained thirdparty valuation service utilizes incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency exchange rates london interbank offered rates swap rates inputs applicable observable commonly quoted intervals total estimated fair values aggregate shortterm longterm senior unsecured notes term loan facility determined using level inputs based quoted market values approximately billion billion december respectively carrying values billion billion december respectively level inputs measured assets acquired liabilities assumed fair value nonrecurring basis connection acquisition immunomedics inc immunomedics see note acquisitions additional information connection collaborations equity arrangements entered separately pionyr immunotherapeutics inc pionyr tizona therapeutics inc tizona also measured fair values exclusive options acquire remaining outstanding capital stock pionyr tizona nonrecurring basis see note collaborations arrangements additional information measured iprd intangible assets acquired connection acquisition kite pharma inc kite fair value nonrecurring basis recognized pretax impairment charges million million respectively fair values acquired iprd assets estimated based probabilityadjusted discounted cash flow calculations using level fair value measurements inputs include estimated revenues costs probability technical regulatory success discount rates amounts capitalized iprd subject impairment testing completion abandonment associated rd efforts see note goodwill intangible assets additional information level liabilities contingent consideration liabilities material december policy recognize transfers level classification actual date event change circumstances caused transfer transfers level level level periods presented availableforsale debt securities following table summarizes availableforsale debt securities december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated millions cost gains losses fair value cost gains losses fair value us treasury securities certificates deposit us government agencies securities nonus government securities corporate debt securities residential mortgage asset backed securities total following table summarizes classification availableforsale debt securities consolidated balance sheets millions december december cash cash equivalents shortterm marketable securities longterm marketable securities total accrued interest receivable excluded fair value amortized cost basis availableforsale debt securities million million december respectively recorded prepaid current assets consolidated balance sheets writeoffs accrued interest receivable years ended december following table summarizes availableforsale debt securities contractual maturity december millions amortized cost fair value within one year one year five years five years total following table summarizes availableforsale debt securities unrealized loss position less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated millions losses fair value losses fair value losses fair value december corporate debt securities held total positions unrealized loss position december respectively aggregated gross unrealized losses availableforsale corporate debt securities material accordingly impairments recognized years ended december gross realized gains gross realized losses availableforsale debt securities material years ended december derivative financial instruments operations foreign countries expose us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies primarily euro manage risk may hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities denominated nonfunctional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded income expense net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturities months less upon executing hedging contract quarterly thereafter assess hedge effectiveness using regression analysis unrealized gains losses aoci reclassified product sales respective hedged transactions affect earnings majority gains losses related hedged forecasted transactions reported aoci december expected reclassified product sales within months cash flow effects derivative contracts years ended december included within net cash provided operating activities consolidated statements cash flows notional amounts foreign currency exchange contracts outstanding totaling billion billion december respectively derivative contracts allow us right offset assets liabilities presented amounts gross basis following table summarizes classification fair values derivative instruments consolidated balance sheets december asset derivatives liability derivatives fair fair millions classification value classification value derivatives designated hedges foreign currency exchange contracts prepaid current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts prepaid current assets accrued liabilities total derivatives designated hedges total derivatives december asset derivatives liability derivatives fair fair millions classification value classification value derivatives designated hedges foreign currency exchange contracts prepaid current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts prepaid current assets accrued liabilities total derivatives designated hedges total derivatives following table summarizes effect foreign currency exchange contracts consolidated financial statements year ended december millions derivatives designated hedges gain loss recognized aoci gain loss reclassified aoci product sales derivatives designated hedges gain loss recognized income expense net time time may discontinue cash flow hedges result record related amounts income expense net consolidated statements income discontinuances cash flow hedges years presented december held foreign currency exchange contracts following table summarizes potential effect offsetting foreign currency exchange contracts consolidated balance sheets gross amounts offset consolidated balance sheets amounts assetsliabilities gross amounts gross amounts offset presented derivative recognized consolidated consolidated balance financial cash collateral net amount millions assetsliabilities balance sheets sheets instruments receivedpledged legal offset december derivative assets derivative liabilities december derivative assets derivative liabilities acquisitions forty seven inc forty seven april acquired issued outstanding common stock forty seven clinicalstage immunooncology company focused developing therapies targeting cancer immune evasion pathways specific cell targeting approaches price per share cash total consideration billion net acquired cash result forty seven became whollyowned subsidiary forty sevens lead program magrolimab investigational monoclonal antibody clinical development treatment myelodysplastic syndrome acute myeloid leukemia nonhodgkin lymphoma solid tumors accounted transaction asset acquisition since lead asset magrolimab represented substantially fair value gross assets acquired acquisition date recorded billion charge representing acquired iprd asset alternative future use acquired inprocess research development expenses consolidated statements income connection acquisition recorded million assets acquired primarily consisting deferred tax assets liabilities assumed material also recorded stockbased compensation expense million related cash settlement unvested forty seven employee stock awards attributable postacquisition services primarily recorded research development expenses consolidated statements income year ended december immunomedics september entered agreement plan merger agreement plan merger acquire immunomedics company focused development antibodydrug conjugate adc technology immunomedics researches develops biopharmaceutical products particularly antibodybased products patients solid tumors blood cancers manufactures markets trodelvy trodelvy tropdirected adc developed immunomedics first adc fda approved treatment adult patients metastatic triplenegative breast cancer mtnbc october acquisition completed immunomedics became whollyowned subsidiary gilead financial results immunomedics included consolidated financial results year ended december date acquisition immunomedics contributed million revenues immaterial net loss date acquisition december cash consideration acquisition billion consisting billion cash payment outstanding immunomedics common stockholders million cash payment equity award holders immunomedics vested equity awards accelerated vesting stockbased awards attributable precombination period financed acquisition majority proceeds september senior unsecured notes offering additional billion borrowing new senior unsecured term loan facility cash hand see note debt credit facilities additional information acquisition immunomedics accounted business combination using acquisition method accounting method requires among things assets acquired liabilities assumed generally recognized fair value acquisition date fair value estimates assets acquired liabilities assumed based upon valuations using information known knowable date filing changes assumptions estimates could cause impact valuation assets acquired including intangible assets goodwill related tax impacts acquisition well legal contingencies amounts recognized finalized information necessary complete analysis obtained later one year acquisition date also recorded sharebased compensation expense million related cash settlement accelerated sharebased compensation expense attributable post combination period primarily recorded selling general administrative expenses research development expenses consolidated statements income year ended december also recorded acquisitionrelated expenses million primarily representing closing costs related fees selling general administrative expenses consolidated statements income year ended december following table summarizes fair values assets acquired liabilities assumed acquisition date millions amount cash cash equivalents inventories intangible assets finitelived intangible asset acquired iprd outlicense contract deferred income taxes liability related future royalties assets liabilities net total identifiable net assets goodwill total consideration transferred inventories fair value stepup adjustment million included inventories million acquisition date primarily determined estimated selling price finished inventory less cost complete manufacturing process selling effort stepup adjustment recorded cost goods sold consolidated statements income inventory sold customers acquisition date intangible assets finitelived intangible asset billion represents estimated fair value trodelvy mtnbc acquisition date fair value determined applying income approach using unobservable inputs estimate probabilityweighted net cash flows attributable trodelvy mtnbc discount rate discount rate used represents estimated rate market participants would use value intangible asset intangible asset amortized estimated useful life years acquired intangible assets related iprd consist trodelvy hormone receptor positive hr human epidermal growth factor receptor negative metastatic breast cancer trodelvy nonsmall cell lung cancer nsclc trodelvy urothelial cancer estimated aggregate fair value billion acquisition date determined applying income approach using unobservable inputs estimate probabilityweighted net cash flows attributable assets discount rate discount rate used represents estimated rate market participants would use value intangible assets significant assumptions inherent development intangible asset fair values include amount timing projected future cash flows including revenue cost sales research development costs sales marketing expenses probability success discount rate selected measure inherent risk future cash flows assessment assets life cycle competitive trends impacting asset among factors intangible assets related iprd projects considered indefinitelived assets completion abandonment associated rd efforts also recorded intangible asset related license supply agreement third party entered immunomedics prior acquisition agreement third party granted exclusive license develop commercialize trodelvy certain territories asia make certain sales milestones royalty payments us acquisition date fair value million determined estimating probabilityweighted net cash flows attributable outlicense discount rate discount rate represents estimated rate market participants would use value intangible asset intangible asset amortized estimated useful life years straightline basis inputs used valuing identifiable intangibles unobservable considered level fair value measurement disclosure guidance deferred income taxes net deferred tax liability based upon difference estimated book basis tax basis net assets acquired estimate final preacquisition net operating losses immunomedics liability related future royalties assumed liability related funding arrangement originally entered immunomedics rpi finance trust delaware statutory trust rpi prior completion acquisition immunomedics funding agreement rpi right receive certain royalty amounts subject certain reductions based net sales trodelvy calendar quarter term agreement approximately acquisition date fair value liability estimated billion primarily determined based current estimates future royalty payments rpi life arrangement using real options method effective annual interest rate liability amortized using effective interest rate method resulting recognition interest expense years estimated timing amount future expected royalty payments estimated term reassessed reporting period impact changes estimates recognized liability related interest expense prospectively inputs used valuation liability unobservable considered level fair value measurement disclosure guidance liability related future royalties categorized debt primarily included longterm debt net consolidated balance sheets see note debt credit facilities additional information goodwill excess consideration transferred fair values assets acquired liabilities assumed billion recorded goodwill primarily reflects future economic benefits arising assets acquired could individually identified separately recognized goodwill recognized immunomedics expected deductible income tax purposes supplemental pro forma information following pro forma information presents combined results operations gilead immunomedics acquisition immunomedics completed january adjustments give effect pro forma events directly attributable acquisition year ended december millions unaudited total revenues net income loss attributable gilead primary adjustments include postcombination compensation expense million related acceleration unvested sharebased awards immunomedics ii impact additional interest expense connection immunomedics acquisition borrowings well liability related future royalties iii amortization finitelived intangible asset related trodelvy mtnbc beginning april received fda accelerated approval iv amortization acquired immunomedics inventory related trodelvy mtnbc period inventory expected sold beginning april v amortization license supply agreement third party estimated useful life years vi impacts sale marketable securities based use source liquidity fund acquisition vii acquisitionrelated transaction costs unaudited pro forma financial results reflect operating efficiencies potential cost savings may result consolidation operations gilead immunomedics accordingly unaudited pro forma financial results presented informational purposes necessarily indicative actual results operations combined company would acquisition occurred beginning indicative future results operations myr gmbh myr december entered definitive agreement pursuant expect acquire myr german biotechnology company approximately billion cash approximately billion using foreign currency exchange rate december payable upon closing transaction potential future milestone payment million approximately million using foreign currency exchange rate december upon fda approval hepcludex payments subject customary adjustments myr focuses development commercialization therapeutics treatment chronic hepatitis delta virus hdv acquisition provide gilead hepcludex conditionally approved european medicines agency ema july treatment chronic hdv infection adults compensated liver disease consummation transaction subject expiration termination waiting period hartscott rodino antitrust improvements act receipt merger control foreign direct investment approvals certain european jurisdictions certain customary closing conditions anticipate closing transaction occur end first quarter expect acquisition myr accounted business combination using acquisition method accounting upon closing inventories following table summarizes inventories december millions raw materials work process finished goods total reported inventories longterm assets total amounts reported longterm assets primarily consisted raw materials december total inventories december include fair value adjustments resulting immunomedics acquisition recognized future periods see note acquisitions additional information inventory write charges year ended december material year ended december recorded inventory write charges million million related slow moving excess raw material work process inventory primarily due lower long term demand hcv products year ended december recorded inventory write charges million million related excess raw materials primarily due sustained decrease demand harvoni property plant equipment following table summarizes property plant equipment net december millions land land improvements buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment construction progress subtotal less accumulated depreciation amortization total unamortized capitalized software costs included office computer equipment million million december respectively capitalized interest construction inprogress included property plant equipment interest capitalized material longlived assets net book value property plant equipment less office computer equipment united states billion december billion december billion december corresponding amount international locations million december million december million december individual international locations accounted less total balances goodwill intangible assets goodwill following table summarizes changes carrying amount goodwill millions amount balance december goodwill resulting acquisition immunomedics balance december perform annual goodwill impairment assessment fourth quarter earlier impairment indicators exist december accumulated goodwill impairment losses intangible assets following table summarizes intangible assets net december december gross foreign currency gross foreign currency carrying accumulated translation net carrying carrying accumulated translation net carrying millions amount amortization adjustment amount amount amortization adjustment amount finitelived assets intangible asset sofosbuvir intangible asset axicabtagene ciloleucel dlbcl intangible asset trodelvy mtnbc total finitelived assets indefinitelived assets iprd total intangible assets includes indefinitelived assets iprd recognized part immunomedics acquisition october see note acquisitions additional information aggregate amortization expense related finitelived intangible assets billion billion billion years ended december respectively primarily included cost goods sold consolidated statements income amounts capitalized iprd subject impairment testing completion abandonment associated rd efforts performed quantitative impairment testing iprd intangible assets using probabilityweighted income approach discounts expected future cash flows present value using discount rate iprd impairment charges recorded performed quantitative impairment testing iprd intangible assets using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar profile represents rate market participants would use value intangible assets discounted cash flow models used valuing intangible assets also require use level fair value measurements inputs including estimated revenues costs probability technical regulatory success comparison assessment used lower estimated revenues due changes estimated market opportunities new therapies combinations existing therapies approved lower estimated revenues reduced fair value iprd intangible assets primarily related axicabtagene ciloleucel treatment indolent bcell nonhodgkin lymphoma inhl carrying value resulting recognition impairment charge million recorded within research development expenses consolidated statements income concluded kite program justify efforts based totality clinical data gathered discontinued program result carrying value iprd relating kite program written zero recorded impairment charge million within research development expenses consolidated statements income following table summarizes estimated future amortization expense associated finitelived intangible assets december millions amount thereafter total financial information accounts receivable net following table summarizes accounts receivable net december millions accounts receivable less chargebacks less cash discounts less allowances credit losses accounts receivable net accrued liabilities following table summarizes components accrued liabilities december millions compensation employee benefits income taxes payable allowance sales returns accrued expenses total collaborations arrangements continue pursue licensing strategic collaborations similar arrangements third parties equity investments third parties focused development commercialization certain products product candidates arrangements may involve two parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities arrangements may include nonrefundable upfront payments expense reimbursements payments us options acquire certain rights contingent obligations us potential development regulatory milestone payments andor salesbased milestone payments royalty payments revenue profitsharing arrangements costsharing arrangements arcus biosciences inc arcus may acquired million shares common stock arcus publicly traded oncologyfocused biopharmaceutical company approximately million secondary equity offering separately may entered transaction arcus included entry option license collaboration agreement arcus collaboration agreement common stock purchase agreement investor rights agreement together subsequently amended arcus stock purchase agreements upon closing arcus collaboration agreement arcus stock purchase agreements july made upfront payment million acquired approximately million additional shares arcus common stock million accordance terms arcus collaboration agreement arcus stock purchase agreements total million initial cash payments made agreements direct transactional costs recorded million equity investment calculated based arcus closing stock price closing date transaction recorded equity investments arcus longterm assets consolidated balance sheets investments subject contractual lockup provisions period years closing date agreements subject certain conditions account equity investments arcus fair value changes fair value recognized income expense net reporting period remaining million attributed acquired license option rights million representing iprd assets alternative future use million issuance premium equity purchase million direct transactional costs amounts expensed acquired inprocess research development expenses year ended december consolidated statements income event subsequent december january amended restated common stock purchase agreement pursuant acquired approximately million additional shares arcus common stock million february result combined existing share holdings million shares arcus representing approximately issued outstanding voting stock arcus immediately following closing transaction gilead right optin current future investigational product candidates emerge arcus research portfolio ten years following closing transaction upon exercise option program unless arcus opts according terms arcus collaboration agreement companies codevelop share global development costs cocommercialize share profits us obtain exclusive rights commercialize optioned programs outside us subject rights arcus existing partners pay arcus tiered royalties ranging high teens low twenties net sales arcus collaboration agreement subject certain limited exceptions required provide million arcus second anniversary agreement may pay additional million option fourth sixth eighth anniversaries agreement unless terminated early ongoing research development support extend collaboration term years accordingly year ended december recorded million charge representing contractually committed payment acquired inprocess research development expenses consolidated statements income arcus collaboration agreement potentially provide billion optin milestone payments respect current clinical product candidates payments triggered arcus collaboration agreement arcus stock purchase agreements right purchase additional shares arcus arcus next five years maximum outstanding voting stock subject threeyear standstill restricting ability acquire voting stock arcus exceeding issued outstanding voting stock arcus subject certain exceptions additionally agreed dispose equity securities arcus prior second anniversary closing arcus stock purchase agreements without prior consent arcus subject certain exceptions pionyr june entered transaction pionyr privately held company pursuing novel biology field immunooncology included entry two separate merger agreements one contemplating initial acquisition equity interest pionyr providing us exclusive option subject certain terms conditions acquire remaining outstanding capital stock pionyr together pionyr merger option agreements research development service agreement july closed transaction pionyr paid million cash accrued additional million payable subject certain customary adjustments pionyrs shareholders accordance terms pionyr merger option agreements account investment pionyr using equity method accounting equity interest provides us ability exercise significant influence pionyr investment pionyr consisting transaction price noted transaction costs exceeded prorata portion pionyr 's net assets transaction closing determined resulting basis difference primarily relates pionyrs iprd alternative future use pionyr business defined asc business combinations result immediately recorded charge basis difference million acquired inprocess research development expenses consolidated statements income year ended december estimated fair value exclusive option acquire remaining outstanding capital stock pionyr approximately million based probability weighted option pricing model using unobservable inputs considered level fair value measurement disclosure guidance estimated amount recorded longterm assets consolidated balance sheets first anniversary closing date may choose exercise exclusive option purchase remaining equity interest pionyrs current shareholders million option exercise fee billion potential future milestone payments upon achievement certain development regulatory milestones case subject certain negotiated adjustments option purchase expire following earliest occurrence specified events including delivery data following completion certain phase b trials pionyr research development service agreement made initial cash funding million recorded charge acquired inprocess research development expenses consolidated statements income year ended december addition committed provide additional payments million pionyr upon achievement certain development milestones accrued million milestone payments related initiation two phase studies charge research development expenses consolidated statements income year ended december subsequently february milestone cash payments million made tizona july entered transaction tizona privately held company developing cancer immunotherapies included entry two separate merger agreements one contemplating initial acquisition equity interest tizona providing us exclusive option subject certain terms conditions acquire remaining outstanding capital stock tizona together tizona merger option agreements development agreement august closed transaction tizona paid million cash tizonas shareholders accordance terms tizona merger option agreements account investment tizona using equity method accounting equity interest provides us ability exercise significant influence tizona investment tizona consisting transaction price noted transaction costs exceeded prorata portion tizonas net assets transaction closing determined resulting basis difference primarily relates tizonas iprd alternative future use tizona business defined asc business combinations result year ended december immediately recorded charge basis difference million acquired inprocess research development expenses consolidated statements income estimated fair value exclusive option acquire remaining outstanding capital stock tizona approximately million based probability weighted option pricing model using unobservable inputs considered level fair value measurement disclosure guidance estimated amount recorded longterm assets consolidated balance sheets first anniversary closing date may choose exercise exclusive option purchase remaining equity interest tizonas current shareholders billion including option fee potential future milestone payments upon achievement certain development regulatory milestones case subject certain negotiated adjustments option purchase expire following earliest occurrence specified events including delivery data following completion certain phase b trials tizona development agreement committed provide funding tizona million recorded acquired inprocess research development expenses consolidated statements income year ended december tango therapeutics inc tango august entered transaction tango privately held company pursuing innovative targeted immune evasion therapies patients cancer proprietary crisprenabled functional genomics target discovery platform included entry amended restated research collaboration license agreement stock purchase agreement together tango collaboration stock purchase agreements upon entering transaction made upfront payment million million equity investment tango representing approximately issued outstanding voting stock tango immediately following transaction accordance terms tango collaboration stock purchase agreements year ended december recorded million upfront expense acquired inprocess research development expenses consolidated statements income equity investment tango recorded cost less impairment adjusted observable price changes orderly transactions identical similar investments tango tango collaboration stock purchase agreements gilead right option programs sevenyear collaboration million per program optin extension milestone payments products tango opts codevelop copromote parties equally split profits losses well development costs us products tango opt codevelop copromote pay tango low double digit tiered royalties net sales provide tango milestone payments royalties sales outside us jounce therapeutics inc jounce september entered transaction jounce publicly traded company developing novel cancer immunotherapies included entry license registration rights stock purchase agreements together jounce license stock purchase agreement october closed transaction made total payment million accordance terms jounce license stock purchase agreement recorded million equity investment longterm assets consolidated balance sheets representing approximately issued outstanding voting stock jounce immediately following transaction calculated based jounces closing stock price closing date transaction year ended december recorded million upfront expense acquired inprocess research development expenses consolidated statements income addition provide million future potential clinical regulatory commercial milestone payments upon achievement certain milestones pay jounce royalties ranging high single digit midteens based upon worldwide sales subject certain adjustments galapagos filgotinib collaboration closed license collaboration agreement galapagos clinicalstage biotechnology company based belgium development commercialization filgotinib jakselective inhibitor evaluated inflammatory disease indications filgotinib agreement upon closing made upfront license fee payment equity investment galapagos subscribing million new ordinary shares galapagos price per share equity investment net issuance premium million amended terms filgotinib agreement agreed amend terms terms filgotinib agreement amended agreement obtained exclusive worldwide royaltybearing sublicensable license filgotinib products containing filgotinib december galapagos eligible receive us potential future development regulatory milestonebased payments million salesbased milestone payments million plus tiered royalties global net sales ranging exception certain cocommercialization territories profits would shared equally cocommercialization territories uk germany france italy spain belgium netherlands luxembourg shared global development costs filgotinib equally termination agreement could countrybycountry basis depends circumstances including expiration royalty term cocommercialization territories sale generic product material breach either party could also terminate entire agreement without cause following certain period december following type meeting fda discuss points raised complete response letter related new drug application filgotinib treatment rheumatoid arthritis gilead galapagos agreed amend agreement galapagos assume development manufacturing commercialization certain rights filgotinib europe phased transition including transfer filgotinibs marketing authorization galapagos parties intend transfer activities december complete transition december transfer subject applicable local legal regulatory consultation requirements beginning january galapagos bears development costs certain studies lieu equal cost split contemplated agreement commercial economics filgotinib europe transfer galapagos january subject payment tiered royalties net sales europe gilead starting connection amendments agreement gilead agreed irrevocably pay galapagos million approximately million subject certain adjustments higher budgeted development costs total amount gilead paid million approximately million january pay additional million approximately million pay million approximately million accrued full amount liability charge research development expenses consolidated statements income year ended december addition galapagos longer eligible receive future milestone payments relating filgotinib europe periods presented payments galapagos us development costs milestones material global collaboration august closed option license collaboration agreement galapagos collaboration agreement subscription agreement galapagos subscription agreement galapagos pursuant parties entered global collaboration covers galapagos current future product portfolio filgotinib upon closing paid billion license option rights million new ordinary shares galapagos subscription price per share fair value billion included issuance discount million calculated based galapagos closing stock price date closing galapagos subscription agreement remaining billion payment recorded within acquired inprocess research development expenses consolidated statements income year ended december pursuant galapagos subscription agreement issued warrants confer right subscribe time time number new shares issued galapagos sufficient bring number shares owned us issued outstanding shares time exercises exercised warrant subscribe million ordinary shares galapagos per share purchased shares open market aggregate fair value million brought number shares owned us million approximately shares issued outstanding equity investment galapagos initially classified longterm assets consolidated balance sheets subject contractual lockup provisions subject year standstill restricting ability acquire voting securities galapagos exceeding issued outstanding voting securities galapagos agreed without prior consent galapagos dispose equity securities galapagos prior second anniversary closing galapagos subscription agreement dispose equity securities galapagos thereafter fifth anniversary closing galapagos subscription agreement disposal would less issued outstanding voting securities galapagos subject certain exceptions termination events two designees appointed galapagos board directors initial contractual lockup provision certain galapagos shares expire august corresponding equity investment balance million included within prepaid current assets consolidated balance sheets december december gileads total investment balance galapagos billion billion respectively elected fair value option account equity investment galapagos whereby investment marked market earnings reporting period based market price galapagos shares believe fair value option best reflects underlying economics investment year ended december recorded pretax unrealized loss billion related investment galapagos income expense net consolidated statements income due decline galapagos stock price see note fair value measurements additional information galapagos collaboration agreement exclusive license development commercialization glpg phase candidate idiopathic pulmonary fibrosis territories option participate development commercialization galapagos current future clinical programs entered clinical development first ten years collaboration subject extension certain circumstances may exercise option program receipt data package completed qualifying phase study program certain circumstances first phase study glpg receives marketing approval us pay galapagos million well tiered royalties described respect programs galapagos current future pipeline exercise option program pay million option exercise fee per program addition galapagos receive tiered royalties ranging net sales territories galapagos product optioned us including glpg exercise option program parties share equally development costs mutually agreed commercialization costs incurred subsequent exercise option galapagos retains exclusive commercialization rights optioned programs european union uk iceland norway lichtenstein switzerland exclusive commercialization rights countries globally may terminate collaboration entirety programby program countrybycountry basis advance notice well following customary termination events galapagos delivered us data package respect option participate development commercialization glpg phase b candidate osteoarthritis galapagos collaboration agreement declined exercise november addition gilead galapagos announced decision halt isabela phase clinical studies glpg february janssen compleraeviplera odefsey entered license collaboration agreement janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssens nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved us european union sold brand name complera us eviplera european union agreement amended expand collaboration include another product containing janssens rilpivirine emtricitabine tenofovir alafenamide odefsey amended agreement janssen granted us exclusive license compleraeviplera odefsey worldwide retained rights distribute combination products certain countries outside us neither party restricted combining drugs drug products except similar components compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries selling party financial provisions amendment selling party sets price combined products parties share revenues based ratio net selling prices partys components subject certain restrictions adjustments retain specified percentage janssens share revenues including major markets sales products included product sales janssens shares revenues included cost goods sold consolidated statements income cost goods sold relating janssens shares million million million years ended december respectively termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years symtuza amended license collaboration agreement janssen develop commercialize fixeddose combination janssens darunavir cobicistat emtricitabine tenofovir alafenamide combination approved us european union july september respectively sold brand name symtuza terms amendment granted janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property related cobicistat emtricitabine tenofovir alafenamide gilead compounds exclusive supplier gilead compounds neither party restricted combining drugs drug products except similar components symtuza janssen sets price symtuza parties share revenue based ratio net selling prices partys components subject certain restrictions adjustments intellectual property license supply obligations related gilead compounds accounted single performance obligation license deemed predominant item revenue share relates recognize share symtuza revenue period corresponding sales symtuza janssen occur record share symtuza revenue product sales consolidated statements income primarily supply gilead compounds janssen symtuza see note revenues additional information revenue recognized periods presented termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term janssen may terminate agreement without cause countrybycountry basis case gilead right become selling party countryies product launched market fewer years janssen may also terminate entire agreement without cause japan tobacco inc japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights paid royalty us based product sales japan agreement responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts pay royalty japan tobacco based product sales japan tobacco also marketed distributed certain products hiv portfolio japan paid royalty us based product sales received approval stribild genvoya elvitegravircontaining products respectively sales products included product sales royalties due japan tobacco based product sales included cost goods sold royalties due japan tobacco based product sales japan included royalty contract revenues consolidated statements income royalty expenses recognized million million million years ended december respectively royalty income recognized material periods presented effective december entered agreement japan tobacco acquire rights market distribute certain products hiv portfolio japan expand rights develop commercialize elvitegravir include japan responsible marketing products january terms agreement paid japan tobacco million cash million paid upfront payment remaining million paid recognized intangible asset million reflecting estimated fair value marketingrelated rights acquired japan tobacco remaining million recorded prepaid current assets consolidated balance sheets intangible asset amortized nine years representing period majority benefits expected derived applicable products hiv portfolio amortization expense classified selling expense recorded selling general administrative expenses consolidated statements income termination agreement may product country basis depend circumstances including material breach either party expiry royalty payment term may also terminate entire agreement without cause gadeta july entered collaboration arrangement gadeta made purchase equity gadeta gadetas shareholders determined gadeta vie primary beneficiary power direct activities gadeta significantly impact economic performance upon initial consolidation gadeta recorded million noncontrolling interest primarily reflecting acquired intangible assets related iprd consolidated balance sheets year ended december effectively terminated agreement gadeta upon effective termination ceased controlling interest deconsolidated vie removing related net assets noncontrolling interest million consolidated balance sheets net loss deconsolidation material bristolmyers squibb company bms north america collaboration arrangement bms develop commercialize single tablet regimen containing truvada bmss sustiva efavirenz us canada combination sold brand name atripla bms structured collaboration joint venture operated limited liability company consolidated december terminated bmss participation collaboration following launch generic version sustiva us became sole owner joint venture bms permitted commercialize atripla us canada entitled receive us certain fees based net sales atripla declining annual scale bms supplies sustiva us cost plus markup threeyear period may terminate supply agreement notice period bms notified us voluntary termination supply agreement years ended december recorded million million million respectively fee expenses within cost goods sold consolidated statements income europe gilead sciences ireland uc whollyowned subsidiary bms collaboration agreement sets forth terms conditions bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bmss estimated net selling price efavirenz european territory parties also formed limited liability company hold marketing authorization atripla european territory starting except limited number activities jointly managed parties longer coordinate detailing promotional activities european territory responsible manufacturing product distribution inventory management warehousing primary responsibility regulatory activities local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories bms promote atripla general parties share revenues outofpocket expenses proportion net selling prices components atripla truvada efavirenz december efavirenz purchased bms bmss estimated net selling price efavirenz european territory included inventories consolidated balance sheets september bms elected voluntarily terminate agreement effective march post termination bms permitted commercialize atripla european territory entitled receive us certain fees based net sales atripla declining annual scale threeyear period following effective date termination collaboration arrangements individually significant entered several collaborative equity investments licensing arrangements well similar arrangements consider individually material recorded upfront collaboration expenses related arrangements million million million years ended december respectively within acquired inprocess research development expenses consolidated statements income cash payments made related equity investments years ended december million million million respectively primarily recorded within prepaid current assets longterm assets consolidated balance sheets financial terms arrangements may required make payments upon achievement various developmental regulatory commercial milestones could significant future milestone payments reflected consolidated statements income corresponding events become probable connection regulatory approvals milestone payments made capitalized intangible assets amortized cost goods sold terms collaboration arrangements addition may required pay significant royalties future sales products related arrangements commercialized payment amounts however contingent upon occurrence various future events high degree uncertainty occurrence debt credit facilities following table summarizes carrying amount borrowings various financing arrangements millions december type borrowing issue date due date interest rate senior unsecured november february senior unsecured september september senior unsecured march april senior unsecured september september month libor senior unsecured december december senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured september september month libor senior unsecured september september term loan october october variable senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october senior unsecured september october senior unsecured september september senior unsecured september september senior unsecured september october senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october total senior unsecured notes term loan facility liability related future royalties total debt net less current portion longterm debt obligations net total longterm debt net senior unsecured notes september issued senior unsecured notes consisting million principal amount floating rate notes due september million principal amount floating rate notes due september together floating rate notes ii billion principal amount senior notes due september million principal amount senior notes due october billion principal amount senior notes due october billion principal amount senior notes due october billion principal amount senior notes due october terms summarized table february repaid maturity million principal balance related senior unsecured notes september repaid maturity billion principal balance related senior unsecured notes repaid billion senior unsecured notes upon maturity january repaid billion senior unsecured notes prior april maturity senior unsecured fixed rate notes may redeemed option redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus makewhole premium defined indenture senior unsecured fixed rate notes also call feature exercisable option redeem notes par whole part dates ranging one month two years prior maturity case accrued unpaid interest also required redeemed date redemption september floating rate notes also call feature exercisable option redeem notes par whole part approximately two years prior maturity event occurrence change control downgrade rating senior unsecured notes investment grade moodys investors service inc sp global ratings holders may require us purchase portion notes price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase required comply certain covenants senior unsecured notes december violation covenants term loan facility september entered commitment letter group institutional lenders provide threeyear senior unsecured term loan facility aggregate principal amount billion pursuant commitment letter october connection acquisition immunomedics entered term loan credit agreement term loan facility borrowed aggregate principal amount billion term loan facility contains customary representations warranties affirmative negative covenants events default term loan facility bears interest eurodollar rate plus applicable percentage defined term loan facility may terminate reduce amount borrowed term loan facility whole part time without premium penalty liability related future royalties connection acquisition immunomedics assumed liability related funding arrangement originally entered immunomedics rpi prior completion acquisition immunomedics liability related future royalties primarily included longterm debt net consolidated balance sheets see note acquisitions additional information revolving credit facilities may entered billion fiveyear revolving credit facility agreement maturing may revolving credit facility june terminated revolving credit facility december amounts outstanding revolving credit facility june entered new billion fiveyear revolving credit facility maturing june revolving credit facility terms substantially similar revolving credit facility revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions december amounts outstanding revolving credit facility revolving credit facility contains customary representations warranties affirmative negative covenants events default december compliance covenants loans revolving credit facility bear interest either eurodollar rate plus applicable percentage ii base rate plus applicable percentage defined revolving credit facility agreement may terminate reduce commitments may prepay loans new credit facility whole part time without premium penalty contractual maturities financing obligations following table summarizes aggregate future principal maturities senior unsecured notes term loan facility december millions amount thereafter total interest expense interest expense debt credit facilities related contractual coupon rates amortization debt discount issuance costs million billion billion respectively leases operating leases consist primarily properties equipment administrative manufacturing rd activities leases include options extend terms years include options terminate lease within one year lease commencement date december material finance leases operating lease expense including variable costs shortterm leases million million respectively operating lease expense prior lease accounting standard million following table summarizes balance sheet information related operating leases december millions except weighted average amounts classification rightofuse assets net longterm assets lease liabilities current accrued liabilities lease liabilities noncurrent longterm obligations weighted average remaining lease term years years weighted average discount rate following table summarizes supplemental information related operating leases year ended december millions cash paid amounts included measurement lease liabilities rightofuse assets obtained exchange lease liabilities following table summarizes maturity analysis operating lease liabilities showing aggregate lease payments december millions amount thereafter total undiscounted lease payments less imputed interest total discounted lease payments commitments contingencies legal proceedings party various legal actions significant described recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine material loss reasonably possible loss range loss estimated disclose possible loss possible determine outcome matters unless otherwise noted outcome including excess accrual expected material reasonably estimate maximum potential exposure range possible loss material accruals matters described consolidated balance sheets december litigation related sofosbuvir acquired pharmasset inc acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hcv received approval fda sofosbuvir known commercially sovaldi sofosbuvir also included marketed hcv products received number litigation claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit predict ultimate outcome claims range loss aware patents patent applications owned third parties may future alleged parties cover use hcv products third parties obtain valid enforceable patents successfully prove infringement patents hcv products could required pay significant monetary damages predict ultimate outcome intellectual property claims related hcv products spent continue spend significant resources defending claims litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii idenix udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringes us patent patent prevailed phases litigation concerning patent us supreme court denied idenixs petition certiorari also idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringes us patent nos patent patent court transferred massachusetts litigation us district court district delaware prior trial idenix committed give us covenant sue respect claims arising patent related sofosbuvir withdrew patent trial jury trial held patent jury found willfully infringed asserted claims patent awarded idenix billion past damages judge invalidated idenixs patent vacated jurys award billion past damages idenix appealed decision us court appeals federal circuit cafc october cafc issued opinion affirming trial courts decision patent invalid april cafc denied idenixs petition rehearing en banc january us supreme court denied idenixs petition review making judgment idenix final litigation university minnesota university minnesota university obtained us patent patent purports broadly cover nucleosides antiviral anticancer activity university filed lawsuit us us district court district minnesota alleging commercialization sofosbuvircontaining products infringes patent believe patent invalid infringed continued commercialization sofosbuvir court granted motion transfer case california also filed petitions inter partes review us patent trademark office patent trial appeal board ptab alleging asserted claims invalid anticipation obviousness ptab instituted one petitions scheduled merits hearing february us district court northern district california stayed litigation ptab concludes inter partes review initiated expect occur litigation related axicabtagene ciloleucel october juno therapeutics inc sloan kettering cancer center collectively juno filed lawsuit us us district court central district california alleging commercialization axicabtagene ciloleucel sold commercially yescarta infringes us patent patent jury trial held patent december jury found asserted claims patent valid willfully infringed asserted claims patent jury also awarded juno damages amounts million upfront payment running royalty october date jurys verdict parties filed posttrial motions first quarter trial judge entered judgment april trial judge affirmed jurys verdict enhanced past damages maintained royalties future yescarta sales april filed appeal seeking reverse judgment obtain new trial due errors made trial judge assessing whether accrue liability litigation consolidated financial statements considered various factors including legal factual circumstances case jurys verdict district courts pre posttrial orders current status proceedings applicable law views legal counsel likelihood judgment upheld appeal result review determined accordance applicable accounting standards probable incur material loss result litigation judgment reversed appeal loss expected zero judgment upheld entirety appeal estimate loss fourth quarter approximately billion consists primarily approximately million represents damages yescarta revenues december prejudgment interest thereon ii approximately million represents enhancement past damages iii approximately million royalties yescarta revenues december december estimated loss include postjudgment interest foregoing estimated material december although predict certainty ultimate outcome litigation appeal believe jurys verdict judgment error litigation related bictegravir viiv healthcare company viiv filed lawsuit us us district court delaware alleging commercialization bictegravir sold commercially combination tenofovir alafenamide emtricitabine biktarvy infringes viivs us patent patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe sole asserted claim patent court set trial date january lawsuit viiv seeking billions dollars alleged damages comprised viivs lost profits royalty sales bictegravir launch trial viiv calculates damages based cumulative us revenues biktarvy since launch totaled billion december addition court find liable infringement expect viiv seek royalty sales trial although predict certainty ultimate outcome litigation adverse judgment could result substantial monetary damages including viivs lost profits royalties trial goingforward royalty stream future sales viiv also filed lawsuit us federal court canada alleging activities relating bictegravir compound infringed viivs canadian patent patent issued shionogi co ltd viiv patent compound patent covering viivs dolutegravir believe bictegravir infringe claims patent january court held summary trial assess viivs infringement allegations april court determined bictegravir infringe claims patent dismissed case viiv appealed decision argument appeal expected take place later november december viiv filed lawsuits france germany ireland uk asserting relevant national designations european patent ep australia asserting australian patent japan asserting japanese patent korea asserting korean patent nos kr patents relate molecules viiv claims would act integrase inhibitors believe bictegravir infringe claims viivs patents filed opposition european patent office epo requesting revocation ep epo hearing scheduled filed petition korean intellectual property office requesting invalidation kr following trial tribunal korean intellectual property trial appeal board found kr invalid viiv may appeal decision court germany scheduled hearing issue infringement april jurisdictions extent claims viivs patents interpreted cover bictegravir believe claims invalid predict ultimate outcome intellectual property claims related bictegravir litigation relating preexposure prophylaxis august filed petitions requesting inter partes review us patent nos collectively hhs patents ptab hhs patents assigned us department health human services hhs purport claim process protecting primate host infection immunodeficiency retrovirus administering combination emtricitabine tenofovir tdf prior exposure host immunodeficiency retrovirus process commonly known preexposure prophylaxis prep november us department justice filed lawsuit us us district court delaware alleging sale truvada descovy use prep infringes hhs patents february ptab declined institute petitions inter partes review hhs patents april filed breach contract lawsuit us federal government court federal claims alleging violations four material transfer agreements mtas related research underlying hhs patents clinical trial agreement cta us centers disease control prevention related prep research although predict certainty ultimate outcome litigation matters believe us federal government breached mtas cta truvada descovy infringe hhs patents hhs patents invalid prior art descriptions truvadas use prep postexposure prophylaxis well physicians patients using claimed methods years hhs filed applications patents trial date lawsuit district court delaware set may litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug sale generic versions products earlier patent expiration would significant negative effect revenues results operations seek approval generic version product nce status generic company may submit anda fda four years branded products approval starting december received letters lupin ltd apotex inc shilpa medicare ltd sunshine lake pharma co ltd laurus labs natco pharma ltd macleods pharma ltd hetero labs ltd cipla ltd collectively generic manufacturers indicating submitted andas fda requesting permission market manufacture generic versions certain tenofovir alafenamide tafcontaining products generic manufacturers seek market generic versions odefsey descovy vemlidy generic manufacturers challenged validity four patents listed orange book associated taf others challenged validity two orange booklisted patents associated taf filed lawsuits generic manufacturers intend enforce defend intellectual property european patent claims several parties filed oppositions epo requesting revocation one granted european patents covering sofosbuvir expires epo upheld validity certain claims sofosbuvir patent appealed decision seeking restore original claims several original opposing parties also appealed requesting full revocation appeal hearing scheduled july several parties filed oppositions epo requesting revocation granted european patent relating sofosbuvir expires epo conducted oral hearing opposition upheld claims two original opposing parties appealed requesting full revocation several parties filed oppositions epo requesting revocation granted european patent covering taf expires epo upheld validity claims taf patent three parties appealed decision appeal hearing scheduled march several parties filed oppositions epo requesting revocation granted european patent relating taf hemifumarate expires epo upheld validity claims taf hemifumarate patent three parties appealed decision three parties filed oppositions epo requesting revocation granted european patent covering cobicistat expires epo upheld validity claims cobicistat patent two parties appealed decision appeal process may take several years epo opposition proceedings confident strength patents predict ultimate outcome oppositions unsuccessful defending oppositions patent claims may narrowed revoked patent protection sofosbuvir taf taf hemifumarate cobicistat european union could substantially shortened eliminated entirely patents revoked european patents granted covering compounds exclusivity may based entirely regulatory exclusivity granted ema lose patent protection compounds revenues results operations could negatively impacted years including succeeding year exclusivity lost government investigations related litigation received subpoena us attorneys office northern district california requesting documents related manufacture quality distribution practices complera atripla truvada viread emtriva hepsera letairis cooperated governments inquiry us department justice informed us declined intervene false claims act lawsuit filed two former employees district court granted department justices motion dismiss plaintiffs federal claims april plaintiffs refiled california false claims act california retaliation claims superior court california county san mateo july california attorney general declined intervene case state court complaint unsealed september filed demurrer requesting superior court dismiss plaintiffs claims overruled november sought appeal superior courts order overruling demurrer although predict ultimate outcome lawsuit believe action without merit intend vigorously defend received voluntary request information us attorneys office eastern district pennsylvania requesting information related reimbursement support offerings clinical education programs interactions specialty pharmacies sovaldi harvoni received another voluntary request information related speaker programs advisory boards hcv hbv products october government informed us following investigation declined intervene two false claims act lawsuits us notwithstanding governments declination relators continued pursue lawsuit relating hbv speaker programs advisory boards served us second amended complaint november december lawsuit relating hcv sales marketing issues unsealed relator indicated intends pursue case gilead although predict ultimate outcome lawsuits believe actions without merit intend vigorously defend also received subpoena us attorneys office southern district new york requesting documents related promotional speaker programs hiv cooperating inquiry april health choice advocates llc health choice advocates filed qui tam lawsuit us seal new jersey state court alleging violations new jersey false claims act clinical education programs sovaldi harvoni hcv hiv patient access programs lawsuit seeks available relief new jersey false claims act july new jersey attorney generals office declined intervene lawsuit complaint unsealed may health choice advocates filed qui tam lawsuit seal us texas state court making similar allegations texas medicare fraud prevention act tmfpa lawsuit seeks available relief tmfpa october texas attorney generals office declined intervene lawsuit complaint unsealed health choice advocates previously filed lawsuit making similar allegations federal false claims act various state false claims acts including tmfpa federal court eastern district texas june court entered order dismissing matter without prejudice july although predict ultimate outcome lawsuits believe actions without merit product liability named defendant two class action lawsuits various product liability lawsuits related viread truvada atripla complera stribild plaintiffs allege viread truvada atripla complera andor stribild caused experience kidney bone andor tooth injuries lawsuits pending state federal court california delaware florida new jersey missouri involve plaintiffs plaintiffs cases seek damages relief various grounds alleged personal injury economic loss intend vigorously defend actions believe cases without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages antitrust consumer protection along japan tobacco bms johnson johnson inc named defendants class action lawsuits filed related various drugs used treat hiv including drugs used combination antiretroviral therapy japan tobacco dismissed lawsuit favorable court ruling defendants motion dismiss plaintiffs allege remaining defendants engaged various conduct restrain competition violation federal state antitrust laws state consumer protection laws lawsuits may consolidated pending us district court northern district california lawsuits seek bring claims behalf two nationwide classes one direct purchasers consisting largely wholesales another endpayor purchasers including health insurers individual patients plaintiffs seek damages permanent injunctive relief relief september along generic manufacturers cipla ltd cipla usa inc cipla named defendants class action lawsuit filed us district court northern district california jacksonville police officers fire fighters health insurance trust jacksonville trust behalf endpayor purchasers jacksonville trust claims settlement agreement us cipla settled patent dispute relating patents covering emtriva truvada atripla products permitted generic entry prior patent expiry violates certain federal state antitrust consumer protection laws plaintiffs seek damages permanent injunctive relief relief believe cases without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages could subject permanent injunctive relief awarded favor plaintiffs securities litigation immunomedics several former officers directors named defendants putative class actions filed lawsuits consolidated september plaintiffs filed consolidated complaint november plaintiffs allege immunomedics individual defendants violated federal securities laws connection immunomedics biologics license application trodelvy seek certification class shareholders damages relief consolidated lawsuit pending united states district court district new jersey january immunomedics filed motion dismiss consolidated complaint denied july believe case without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter various firm purchase commitments primarily related active pharmaceutical ingredients api certain inventory related items december commitments next five years approximately billion million million million million amounts related api represent minimum purchase commitments stockholders equity stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions started repurchases program april first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions december remaining authorized repurchase amount programs billion following table summarizes stock repurchases program year ended december millions except per share amounts shares repurchased retired amount average price per share addition repurchases program program repurchased shares common stock withheld us employee restricted stock awards satisfy applicable tax withholding obligations immaterial excluded table use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated additional paidin capital apic based estimated average sales price per issued share excess amounts charged retained earnings dividends following table summarizes cash dividends declared common stock millions except per share amounts dividend per share amount dividend per share amount first quarter second quarter third quarter fourth quarter total restricted stock performance share awards units dividend equivalent rights entitling holders dividend equivalents paid upon vesting share underlying unit february announced board directors declared quarterly cash dividend per share common stock payment date march stockholders record close business march future dividends subject declaration board directors preferred stock million shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series preferred stock outstanding december accumulated comprehensive income following table summarizes changes aoci component net tax unrealized gains unrealized gains foreign currency losses available losses cash translation net forsale debt flow hedges net millions tax securities net tax tax total balance january net unrealized gain loss reclassifications net income net current period comprehensive income loss balance december net unrealized gain reclassifications net income net current period comprehensive income loss balance december net unrealized gain loss reclassifications net income net current period comprehensive income loss balance december amounts reclassified net income gains losses cash flow hedges recorded part product sales consolidated statements income see note derivative financial instruments additional information amounts reclassified net income gains losses availableforsale debt securities recorded part income expense net consolidated statements income income tax impact allocated component comprehensive income material periods presented employee benefits provide sharebased compensation form various types equitybased awards including restricted stock units rsus performance share awards units psus stock options compensation expense recognized consolidated statements income based estimated fair value award grant date estimated fair value rsus based closing price common stock psus estimated fair value based either monte carlo valuation methodology stock price date grant stock option awards estimated fair value based blackscholes option valuation model equity incentive plans may stockholders approved adopted gilead sciences inc equity incentive plan amended plan plan authorized issuance total million shares common stock part forty seven acquisition assumed forty seven inc equity incentive plan subsequently amended restated gilead sciences inc equity incentive plan amended restated plan aggregate amount shares may issued plan assumption date exceed million shares part immunomedics acquisition assumed immunomedics amended restated longterm incentive plan immunomedics plan referred together plan plan plans subsequently merged plan aggregate amount shares may issued immunomedics plan assumption date exceed million shares see note acquisitions additional information settlement stock awards plans broad based incentive plans provide grant equitybased awards including stock options restricted stock units restricted stock awards performance share awards employees directors consultants december total million shares remain available future grant plans stock options plans provide option grants designated either nonqualified incentive stock options stock options granted january nonqualified stock options employee stock options generally vest three four years options exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plans previously authorized available pool shares following table summarizes activity related information stock option plans option grants presented table exercise prices less fair value underlying common stock grant date weighted weightedaverage aggregate average remaining intrinsic shares exercise price contractual term value millions dollars years millions outstanding december granted forfeited expired exercised outstanding december exercisable december expected vest net estimated forfeitures december aggregate intrinsic value represents value closing stock price last trading day year excess weightedaverage exercise price multiplied number options outstanding exercisable total intrinsic value options exercised million million million weightedaverage grant date fair value stock options granted per share per share per share december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years restricted stock performance share awards grant timebased rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus sharebased awards entitle holder receive freely tradable shares common stock upon vesting rsus generally vest three four years date grant fair value rsu equal closing price common stock grant date grant psus vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets actual number common shares ultimately issued calculated multiplying number psus payout percentage ranging awards generally vest committee subcommittee board determined specified market performance goals achieved fair value psu estimated date grant performance objectives defined grants depending terms award fair value date grant determined based either monte carlo valuation methodology closing stock price date grant addition also granted psus certain employees plan vesting awards subject achievement specified individual performance goals typically within one two year period fair value award equal closing price common stock grant date following table summarizes rsu psu activity related information rsus psus weighted weighted average average grant date fair grant date fair millions except per share amounts shares value per share shares value per share outstanding december granted vested forfeited outstanding december weightedaverage grantdate fair value per share excludes shares related grants currently grant date performance objectives yet defined weightedaverage grant date fair value rsus granted per share per share per share weightedaverage grant date fair value psus granted per share per share per share total grant date fair value vested rsus psus million million million total fair value respective vesting dates million million million december million unrecognized compensation cost related unvested rsus psus expected recognized weightedaverage period years employee stock purchase plan employee stock purchase plan international employee stock purchase plan together amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers sixmonth lookback feature well automatic reset feature provides offering period reset new lowerpriced offering offering price new offering period less current offering period espp purchases settled common stock espps previously authorized available pool shares million shares issued espp million total million shares common stock authorized issuance espp million shares available issuance espp december stockbased compensation following table summarizes total stockbased compensation expenses included consolidated statements income year ended december millions cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax pretax stockbased compensation expense year ended december million included million noncash stockbased expense million million accelerated postacquisition stockbased expense related acquisitions immunomedics forty seven respectively see note acquisitions additional information income tax effect year ended december included million income tax expense following us court appeals decision altera corp v commissioner requires related parties intercompany cost sharing arrangement share expenses related stockbased compensation stockbased compensation recognized expense requisite service periods consolidated statements income using straightline expense attribution approach reduced estimated forfeitures estimate forfeitures based historical experience requisite service period could shorter vesting period employee retirement eligible valuation assumptions fair value options granted plan purchases espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts deferred compensation maintain retirement saving plan eligible us employees may defer compensation income tax purposes section k internal revenue code gilead sciences k plan certain foreign subsidiaries maintain defined benefit plans required local regulatory requirements total matching contribution expense gilead sciences k plan defined benefit plans million million million maintain deferred compensation plan directors key employees may defer compensation amounts deferred participants deposited rabbi trust total assets liabilities associated deferred compensation plan million december million december net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock dilutive securities outstanding period potentially dilutive shares common stock resulting assumed exercise outstanding stock options equivalents determined treasury stock method potential shares common stock excluded computation diluted net income per share attributable gilead common shareholders effect would antidilutive million million million respectively following table shows calculation basic diluted net income per share attributable gilead common stockholders year ended december millions except per share amounts net income attributable gilead shares used per share calculation basic dilutive effect stock options equivalents shares used per share calculation diluted net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders diluted income taxes income loss income taxes consists following year ended december millions domestic foreign income income taxes income tax expense benefit consists following year ended december millions federal current deferred state current deferred foreign current deferred income tax expense benefit income tax benefit included billion deferred tax benefit related intangible asset transfers foreign subsidiary ireland united states fourth quarter completed intraentity asset transfer certain intangible assets foreign subsidiary ireland transaction resulted stepup irish taxdeductible basis transferred assets accordingly created temporary difference tax basis exceeded book basis intangible assets result recognized deferred tax asset billion consolidated financial statements expect able realize deferred tax asset resulting intraentity asset transfer impact intangible asset transfer foreign subsidiary united states material income tax expense included million deferred tax charge related transfer acquired intangible assets foreign subsidiary united states transaction result stepup us taxdeductible basis result recognized deferred tax liability million temporary difference book basis exceeded tax basis acquired intangible assets reconciliation federal statutory tax rate applied income taxes effective tax rate summarized follows year ended december federal statutory rate state taxes net federal benefit foreign earnings different rates research credits us tax foreign earnings deferred tax intraentity transfer intangible assets settlement tax examinations acquired iprd related charges changes valuation allowance nontaxable unrealized gain loss investment effective tax rate deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows december millions deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible excess tax basis book basis intangible assets upfront milestone payments research credit carryforwards equity investments liability related future royalties net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities property plant equipment excess book basis tax basis intangible assets total deferred tax liabilities net deferred tax assets liabilities valuation allowance million million december respectively increase valuation allowance primarily related acquired attributes related forty seven immunomedics acquisitions unrealized losses equity method investments reflected acquired iprd expenses valuation allowance decreased million december million december primarily due reduction net operating loss carryforwards asset recognition framework corresponding valuation allowance respect certain foreign jurisdictions december us federal net operating loss tax credit carryforwards approximately billion million respectively start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss start expire utilized state tax credit carryforwards start expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns united states many foreign jurisdictions federal income tax purposes statute limitations open onwards onwards california income tax purposes certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years income tax returns subject audit federal state foreign tax authorities currently examination various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions total unrecognized tax benefits billion billion december respectively recognized would reduce effective tax rate period recognition interest penalties related unrecognized tax benefits included part income tax expense benefit consolidated statements income million million years ended december respectively interest penalties related unrecognized tax benefits year ended december material accrued interest penalties related unrecognized tax benefits million million december respectively december believe reasonably possible unrecognized tax benefits significantly change next months following rollforward total gross unrecognized tax benefits year ended december millions balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period selected quarterly financial information unaudited millions except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income loss net income loss attributable gilead net income loss per share attributable gilead common stockholders basic net income loss per share attributable gilead common stockholders diluted total revenues gross profit product sales net income loss net income loss attributable gilead net income loss per share attributable gilead common stockholders basic net income loss per share attributable gilead common stockholders diluted amounts second quarter included acquired iprd expenses billion per basic diluted share primarily related acquisition forty seven see note acquisitions additional information amounts third quarter included acquired iprd expenses billion per basic diluted share related collaborations investments entered separately arcus pionyr tango tizona million per basic diluted share unrealized losses changes fair value equity investments largely galapagos see note fair value measurements note collaborations arrangements additional information amounts fourth quarter included million per basic diluted share unrealized losses changes fair value equity investments largely galapagos million per basic diluted share acquisitionrelated expenses primarily amortization intangible assets inventory stepup charges accelerated stockbased compensation expenses related acquisition immunomedics see note fair value measurements note acquisitions note collaborations arrangements additional information amounts third quarter included upfront collaboration licensing expenses billion per basic diluted share related collaboration galapagos see note collaborations arrangements additional information amounts fourth quarter included billion favorable tax effect related intraentity intangible asset transfers million pretax net gains equity securities primarily equity investment galapagos partially offset million pretax impairment charge related iprd intangible assets acquired connection acquisition kite pretax writedown charges million slow moving excess raw material work process inventory impact factors resulted net favorable impact per basic share per diluted share see note fair value measurements note inventories note goodwill intangible assets note income taxes additional information item changes disagreements accountants accounting financial disclosure applicable report independent registered public accounting firm stockholders board directors gilead sciences inc opinion internal control financial reporting audited gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion gilead sciences inc company maintained material respects effective internal control financial reporting december based coso criteria indicated accompanying managements report internal control financial reporting managements assessment conclusion effectiveness internal control financial reporting include internal controls immunomedics inc included consolidated financial statements company constituted total assets liabilities respectively december less revenues year ended audit internal control financial reporting company also include evaluation internal control financial reporting immunomedics inc also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes report dated february expressed unqualified opinion thereon basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp san jose california february item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework based evaluation concluded internal control financial reporting effective december scope managements assessment effectiveness internal control financial reporting excluded immunomedics inc gilead acquired business combination october total assets excluding goodwill intangibles assets total liabilities total revenues immunomedics represented approximately less total assets total liabilities total revenues gileads consolidated financial statements year ended december respectively independent registered public accounting firm ernst young llp audited consolidated financial statements included item annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings gilead board directors nominees board structure executive officers applicable delinquent section reports written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance intend disclose future amendments certain provisions code ethics waivers code ethics granted executive officers directors website within four business days following date amendment waiver item executive compensation information required item incorporated reference sections proxy statement headings executive compensation committees board directors compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference item annual report heading equity compensation plan information section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings gilead board directors board processes item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item